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ABSTRACT 
The polyene macrolide amphotericin B (AmB) remains a critically vital antifungal as the 
last line of defense against a wide range of life-threatening fungal pathogen. Despite its clinical 
usage for over half a century, AmB has evaded the development of clinically relevant microbial 
resistance. AmB has been shown to form ion channels similar to that of their protein counterparts, 
which has led to the proposal that AmB kills yeast cells via membrane permeabilization. The 
capacity for ion channel formation and cytotoxicity of AmB are thought to be dependent upon 
membranous sterol, but the role of sterols in this mechanism and whether membrane 
permeabilizaton and biological activity are even linked has remained unclear. Thus, the complete 
understanding of the mechanism of action of AmB would enable the development of new 
antifungals with an improved therapeutic index, as well as guide the pursuit of new antimicrobials 
that evade resistance.  
To elucidate the operative mechanism, we pursued a systematic functional group deletion 
strategy where derivatives of AmB are synthesized lacking a single protic functional group to 
understand its role in AmB’s activity. The C35 hydroxyl group of AmB has been proposed to be 
critical for ion channel formation and so we accessed the derivative lacking the C35 hydroxyl via 
an iterative cross-coupling (ICC) strategy. The resulting derivative maintained the capacity to bind 
membranous ergosterol, but could no longer cause membrane permeabilization. Despite the lack 
of channel activity, this derivative still demonstrated potent fungicidal activity. Deletion of the 
mycosamine sugar yielded a derivative that could no longer bind ergosterol and was completely 
inactive against yeast. Collectively, these results led us to conclude that the primary mechanism 
by which AmB kills yeast is the binding of the ergosterol and that channel formation is a 
complementary mechanism that marginally increases AmB’s potency. This finding suggests that 
toxicity to humans is likely due to the binding of the major mammalian sterol: cholesterol.  
Given the importance of the mycosamine appendage on the binding of sterol, we pursued 
an atomistic understanding of this interaction. The axial C2’ hydroxyl group of AmB has been 
proposed to be critical in binding both sterols. Surprisingly, derivatives lacking or epimerizing the 
C2’ hydroxyl maintained the capacity to bind ergosterol but could no longer bind cholesterol. 
Consistent with sterol binding being the operative mechanism for toxicity, both derivatives 
exhibited potent antifungal activity but no toxicity in human cells and mice. However, synthetic 
access to both derivatives limited their further pursuit. We hypothesized that the sterol selectivity 
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resulted from a ligand-selective allosteric modification and proposed that a similar effect could be 
achieved by derivatization of the accessible C41 carboxylate. Similar to the C2’ modified 
analogues, the new AmB ureas also demonstrated a preferential binding for ergosterol over 
cholesterol. This corresponded with their potent activity against a wide range of fungal pathogens 
as well as their substantial decrease in toxicity to human cells and mice. Despite their decreased 
toxicity, the AmB ureas maintained the ability to evade resistance similar to that of the parent 
compound.  
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CHAPTER 1 
 
CURRENT UNDERSTANDING OF THE MECHANISM OF  
ACTION OF AMPHOTERICIN B 
 
Portions of this chapter were adapted from Endo, M. M.; Cioffi, A. G.; Burke, M. D. Syn. Lett. 
2016, 27, 337-354. 
 
1-1 AMPHOTERICIN B: THE HIGHLY TOXIC ARCHETYPE FOR RESISTANCE-EVASIVE 
ANTIMICROBIALS 
 Invasive fungal infections represent a major health crisis as they are responsible for more 
than 1.5 million deaths each year, a figure exceeding that of either malaria or tuberculosis.1 Fungal 
pathogens account for approximately 10% of all hospital acquired infections with the Candida 
species being the fourth most common microbial systemic infection.2 Furthermore, invasive fungal 
infections may actually be substantially underreported due to the difficulties of diagnosis from the 
high occurrence rate of false negatives in conventional blood cultures.3 Thus, the development of 
a safe and effective antifungal therapy stands to have a significant impact on human global health.  
 In 1953, William Gold and his colleagues isolated the natural product amphotericin B 
(AmB, 1.1) from the soil bacterium Streptomyces nodosus on the banks of the Orinoco River 
region of Argentina.4-7 Prior to this discovery, the prognosis for patients with systemic fungal 
infections was extremely grim as mortality rates were near 100%.8 However, AmB, as a new potent 
and broad-spectrum antifungal dramatically changed the outlook for patients undergoing treatment 
for invasive fungal infections9,10 and has remained the last line of defense against a wide range of 
fungal pathogens.11 
 
Figure 1.1: Chemical structure of amphotericin B (AmB). 
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 Despite its clinical usage for over half a century, there have been very few reports of the 
emergence of clinically relevant resistance to AmB, which is in stark contrast to the history of all 
other clinically significant antimicrobials.11 This may potentially be due to the unselective nature 
of AmB. Generally, less selective pharmacological action is associated with reduced vulnerability 
to resistance as well as increased toxicity.12,13 AmB is exceptionally toxic to human cells, 
especially kidney cells,14 which limits the dose and/or duration of treatment with AmB. Thus, the 
development of less toxic derivatives of AmB would have an incredible impact on human health. 
However, this would require understanding how AmB kills both yeast and human cells. Despite 
extensive studies for over half a century, the mechanism by which AmB is toxic to both cell types 
remains unclear.  
 
1-2 ION CHANNEL HYPOTHESIS 
 One of the earliest studies to attempt to elucidate the mechanism of action for AmB came 
from Kinsky in 1961 where he found that AmB caused a decrease in the dry weight of the mycelial 
mats of Neurospora crassa along with the presence of cytoplasmic constituents in the growth 
medium.15,16 This led Kinsky to conclude that the mechanism of AmB was due to the alteration of 
permeability in the cell's membrane. There were three potential mechanisms to how AmB was 
permeabilizing membranes: gross membrane disruption, ionophoric transport, or discrete ion 
channel formation (Figure 1.2A). Andreoli and coworkers utilized planar lipid bilayer assay to 
observe that the electrical resistance had decreased while the physical integrity of the membrane 
was maintained in the presence of AmB.17 Based on these results, gross membrane disruption is a 
highly unlikely mechanism. To distinguish between the other two mechanisms, Finklestein and 
coworkers compared the electrophysiological properties of AmB with the known ionophore 
valinomycin.18 Valinomycin-mediated conductance increased linearly with concentration, while 
AmB-mediated conductance increased proportionally to a large power of concentration. 
Furthermore, the conductance due to valinomycin addition increased with increasing temperature, 
while AmB-promoted conductance decreased with increasing temperature. These observed 
differences are inconsistent with AmB behaving as an ionophore. However, it was not until 1976 
that the direct observation of the discrete AmB single ion channels was made by Ermishkin and 
coworkers with the planar lipid bilayer technique.19 These single ion channels displayed gating 
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and ion selectivity properties that are typically attributed to protein ion channels. These remarkable 
characteristics have led to AmB becoming the archetype for ion channel-forming small molecules.  
 From 1973-1974, Andreoli,20,21 Finkelstein and Holz,22 and de Kruijff and Demel23 
proposed the barrel-stave model of the AmB ion channel (Figure 1.2B). In this model, eight AmB 
molecules self-assemble to form the transmembrane pore. The hydrophobic polyene is oriented 
outward to interact with the lipid membrane while the hydrophilic polyol lines the inside of the 
channel enabling ion conductance. The barrel-stave model was further advanced by Ermiskin and 
coworkers based on a series of electrophysiology studies using AmB derivatives that were 
modified at the C41 carboxylate and/or C3' ammonium.24 Modification of either charged 
functional group significantly diminished the lifetime of the open channel, which led to the 
proposal that the positive and negative charges of AmB were critical in stabilizing the 
supermolecular channel structure via intermolecular salt-bridges between the C41 carboxylate of 
one AmB and the C3' ammonium on a neighboring AmB (Figure 1.2B and 1.2C). Molecular 
dynamics (MD) studies further supported the hypothesis of this critical intermolecular salt-
bridge.25-27  
 
Figure 1.2: The classical ion channel model for AmB’s activity. (A) Representation of the ion channel in a lipid bilayer membrane. 
(B) Bird’s eye view of the computational model for the putative AmB ion channel. (C) Proposed polar interactions that stabilize 
the ion channel supermolecular structure. 
 To study this putative intermolecular salt-bridge, Murata and coworkers synthesized AmB 
dimers that linked the C41 carboxylate of one AmB molecule with the C3' ammonium of another 
with linkages of varying lengths (Figure 1.3).28 These dimers displayed little to no biological 
activity. However, the dimer with the longest linker 1.4 was able to permeabilize membranes 
similar to AmB in a solution phase NMR-based assay.29 This led to the reasoning that either the 
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intermolecular salt bridge is not present in the ion channel or that a certain distance/flexibility is 
required for this interaction for activity. It is important to note that AmB dimers were also 
synthesized that contained intermolecular linkages between the C41 carboxylate30 or C3' 
ammonium.31 Like the C41-C3' AmB dimer,28 the membrane permeabilization activity of these 
conjugates also had linkage length-dependence. However, antifungal activity was not reported. 
This calls into question the importance of the proposed AmB ion channel to the observed 
antimycotic properties. Furthermore, these covalently modified derivatives contain an inherent 
steric interference, which makes proper evaluation of the potential intermolecular salt bridge 
difficult to assess. 
 
Figure 1.3: Chemical structures of covalently linked dimers of AmB. 
 In addition to the salt bridge, molecular dynamics experiments predicted further 
stabilization of the ion channel from the hydrogen bond network between the C8 hydroxyl of one 
molecule of AmB with the C9 hydroxyl of a neighboring AmB molecule. 26 Interestingly, the C8 
hydroxyl is installed as a post-polyketide synthase (PKS) modification via a cytochrome P450 
monooxygease encoded by the amphL gene. Inactivation of the amphL gene led to the biosynthesis 
of C8-deoxyamphotericin B (C8deOAmB, 1.5).32 This derivative maintained potent antifungal 
activity (~fourfold decrease in activity relative to AmB) demonstrating that either the C8 hydroxyl 
is not necessary in stabilizing the ion channel or that perhaps the ion channel is not required for 
antifungal activity.  
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Figure 1.4: Biosynthetic access to C8deOAmB by inactivation of the post-PKS enzyme responsible for the oxidation at C8. 
C8deOAmB maintained antifungal activity against yeast albeit slightly decreased in potency. 
 The previous studies focused on trying to understand the roles of key functional groups of 
AmB, however early studies with AmB suggested that AmB's mechanism of action was related to 
sterols present in the target organism. Kinsky and coworkers observed that AmB was selectively 
toxic to sterol-containing cells, such as N. crassa protoplasts and rat erythrocytes, while the 
bacteria Bacillus megaterium was completely resistant.33,34 However, due to the complication of 
the cell wall for B. megaterium may prevent AmB from accessing the cellular membrane, Feingold 
utilized the unique model organism Acholeplasma laidlawii which does not biosynthesize sterols 
but will incorporate sterols found in its growth media into its cellular membrane.35 A. laidlawii 
grown with cholesterol-containing media were killed rapidly by AmB, while A. laidlawii grown 
in sterol-free media were completely resistant to AmB.   
 The dependence on sterols for AmB's potent antimicrobial activity along with sterols' 
ability to modulate global membrane properties36-38 led to the idea that AmB's selective activity 
toward organisms containing sterols is due to the sterols altering the physical properties of the 
membrane enabling ion channel formation. This hypothesis was first proposed by Feingold and 
coworkers based on the surprising result that sterols embedded in certain lipid membranes 
attenuated the activity of AmB.39,40 This report used a glucose release assay in which liposomes 
comprised of various lipids contained glucose and upon addition of AmB, the release of glucose 
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from the liposomes was quantified. When treating liposomes comprised of egg lecithin with AmB, 
the expected increase in glucose release was observed upon increasing amounts of embedded 
cholesterol 1.7. Strikingly, liposomes made from the saturated lipids dipalmitoyl lecithin or 
distearoyl lecithin saw the opposite trend where increasing amounts of embedded cholesterol 
resulted in decreasing the observed glucose release.  
 
Figure 1.5: Chemical structures of lipids used to study the effects of various sterols had on the activity of AmB. 
 Recent liposome studies have also observed similar trends in specific biophysical systems. 
Murata and coworkers utilized a 31P-NMR method to measure AmB-mediated potassium flux in 
liposomes comprised of egg yolk PC or 1-palmitoyl-2-oleoyl-sn-3-glycero-phosphocholine 
(POPC, 1.12) lipids.41 When AmB was pre-embedded in the liposomes, increasing amounts of 
cholesterol decreased the amount of potassium flux consistent with trend observed by 
Feingold.39,40 However, when AmB was externally added to the liposomes, potassium flux 
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increased with increasing amounts of cholesterol until a maximum of about 20% cholesterol in the 
liposomes. Additional cholesterol after that point began inhibiting potassium flux. Carreira and 
coworkers also probed the effects of sterols on POPC liposome vesicles of varying sterol 
concentrations via AmB-mediated potassium efflux.42 With ergosterol 1.6 and cholesterol 
liposomes, maximum potassium efflux was observed at 5% sterol content and increasing amounts 
of either sterol resulted in decreased efflux. Interestingly, maximum potassium efflux for 
liposomes with 7-dehydrocholesterol 1.8 or dihydrocholesterol 1.9 were observed at 13% sterol 
content. These results lend support to an indirect sterol-mediated alteration of the membrane to 
promote ion channel formation. 
 Evidence of AmB ion channel activity in certain sterol-free systems has also been utilized 
toward this hypothesis. Hartsel and coworkers utilized a fluorescence-based assay to measure 
AmB-induced potassium leakage from sterol-free egg PC small unilamellar vesicles (SUVs).43 
They reported that at ratios of 1:1000 of AmB to lipid that potassium leakage was observed. 
However, SUVs are poor models for studying membrane phenomena as their small size results in 
a higher radius of curvature, which in turn causes them to be more susceptible to 
permeabilization.44 Furthermore, due to egg PC being derived from natural sources it may contain 
small amounts of cholesterol. Towards these criticisms, AmB's promotion of potassium leakage 
was studied in sterol-free egg PC large unilamellar vesicles (LUVs)45 and POPC LUVs.46 
Interestingly, AmB-mediated permeabilization in these sterol-free vesicles was not observed under 
isoosmotic conditions. The requirement for stressed membranes (either via larger radii of curvature 
or osmotically) to enable membrane permeabilization does question the validity of AmB ion 
channels in sterol-free systems. Ortega-Blake and coworkers utilized patch clamp techniques with 
membranes comprised of asolectin,47 DMPC,47 egg lecithin,48 and isolated E. coli membrane 
extracts.48 The AmB ion channels observed in sterol-free membranes had similar 
electrophysiological properties to the AmB ion channels in the corresponding sterol-containing 
membranes. However, as the authors noted, supraphysiological concentrations of AmB were used 
to form ion channel in these sterol-deficient membranes. Nevertheless, the observation of ion 
channel activity in these sterol-free membranes have been employed to support the notion that 
sterols are not directly interacting with AmB but facilitating AmB ion channel formation by 
modulating the membrane. However, as already stated, there are a number of limitation to these 
studies as they have been applied to only model membranes and not a more physiologically 
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relevant system. Consequently, the ion channel model dictates improving the therapeutic index of 
AmB would require selective ion channel formation in fungal cells over human cells. This would 
be a very challenging problem to solve. Furthermore, it would mean that the toxicity of AmB and 
its channel forming capabilities are intrinsically linked and inseparable. 
 
1-3 DIRECT STEROL BINDING HYPOTHESIS 
 Just three years after the discovery of AmB, Gottlieb and coworkers discovered that an 
extract from carrots protected the mold Penicillium oxalicum from the toxicity of AmB.49 The 
active protective agent in the carrot extract was discovered to be a mixture of sterols, which were 
isolated and found to interfere with AmB's antifungal activity. This interesting protective effect 
would eventually lead to an alternative model based on AmB's observed sterol-dependence. Rather 
than sterols facilitating the insertion of AmB into membrane, Kotler-Brajtburg, et al. proposed that 
AmB directly binds membrane sterols and consequently forms ion channels.50 Specifically, the 
C41 carboxylate,51,52 C3' ammonium,27,51-53 or C2' alcohol54-59 have all been predicted to mediate 
this interaction. Based on this model, the selective toxicity for yeast over human cells stems from 
AmB’s greater affinity for ergosterol (the main fungal sterol) over cholesterol (the main 
mammalian sterol). Early work in support of this model arose from changes in the ultraviolet-
visible (UV/Vis), circular dichromism (CD), and infrared (IR) spectra of AmB with membranes 
containing sterols.60-66 Conversely, it has been argued that the sterol-dependent changes in UV/Vis 
and CD are due to the aggregation of AmB and not a direct binding between AmB and sterols.67 
Towards this understanding, solid-state NMR (SSNMR) with AmB and ergosterol has been 
utilized to study their interaction.68,69 However, in order to gain a real understanding of this binding, 
it is necessary to obtain a complete atomistic understanding of each individual interaction between 
these two small molecules. 
 Chemical modifications to AmB have been done to probe these precise interactions in the 
binding between AmB and sterols. Specifically, acylation of the C3' ammonium and esterification 
of the C41 carboxylate yielding N-acylamphotericin B (NAcAmB, 1.13) and amphotericin B 
methyl ester (AmE, 1.14), respectively were studied to probe the roles of the C41 carboxylate and 
C3' ammonium in this binding (Figure. 1.6).51,52 Liposomes were loaded with one of the sterols in 
Figure 1.5 and treated with AmB, NAcAmB, or AmE. AmB caused permeabilization in liposomes 
with all the sterols tested. In stark contrast, NAcAmB had substantially reduced activity compared 
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to AmB, which suggested that the C3' ammonium hydrogen bonds with the 3β hydroxyl (Figure 
1.5) of the sterols to promote the AmB/sterol interaction consistent with one of the proposed 
models.27,51-53 However, these results are complicated due to the difficulty of discerning between 
the loss in hydrogen bonding capability with the increased steric hindrance in these covalently-
modified derivatives. Interestingly, AmE selectively caused permeabilization in liposomes 
containing either ergosterol or brassicasterol, which have identical hydrophobic tails. This 
selective activity of AmE led to the proposal that the binding between AmB and sterols is stabilized 
by a network of hydrogen bonds with a minor contribution of stabilization between the polyene of 
AmB with the hydrophobic steroidal core. However, loss of the free carboxylate, as in the case of 
AmE, results in a disruption of the hydrogen bond network leading to the van der Waals contact 
between the polyene and steroidal core playing a major role in this binding interaction. However, 
like NAcAmB, this proposal is complicated by the inability to separate the decrease in hydrogen 
bonding capability with the added steric hindrance of the alkyl esters. 
 
Figure 1.6: Chemical structures of two AmB derivatives: NAcAmB and AmE. 
 
Figure 1.7: Chemical structures of tethered derivatives of AmB. 
 The most prominent computational models propose that the axial C2' hydroxyl forms a 
hydrogen bond to the 3β hydroxyl of sterols.54-59 In order to probe this model, AmB derivatives 
that were conformationally restrained by a covalent intramolecular tether positioned the C2' 
hydroxyl in the hypothesized conformation to bind to the 3β hydroxyl of the sterols were 
synthesized. Derivatives 1.16 and 1.17 saw increases in ability to permeabilize ergosterol 
containing liposomes leading to the suggestion that the C2' hydroxyl is critical in this small 
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molecule-small molecule interaction. However, these derivatives saw substantially reduced 
biological activity, once again demonstrating the limitations of covalent modifications in studying 
this unique interaction. Further complicating these models were computational models that 
suggested that the C2' hydroxyl was critical in only binding ergosterol but not cholesterol.58 The 
first chemical modifications to the C2' hydroxyl were synthesized as their C41 methyl esters 
(Figure 1.8).59 Interestingly, the derivative in which the C2' hydroxyl is epimerized 1.18, 
maintained similar antifungal activity and liposome permeabilization to its parent compound. 
However, epimerization and methyl etherification of the C2' hydroxyl 1.19 resulted in substantially 
reduced antifungal activity. Collectively, these studies utilizing covalently modified derivatives 
have contributed to the understanding of the interaction between AmB and sterols. However, the 
lack of specific sterol binding data in addition to the complication of steric hindrance with covalent 
modifications causes interpretation of these results to be highly complex. 
 
Figure 1.8: Chemical structures of AmB derivatives modified at the C2’ position. 
 Modifications to the sterols have also been performed to probe this small molecule-small 
molecule interaction. Enantiomeric cholesterol (ent-cholesterol) was synthesized70 and utilized in 
planar lipid bilayer studies to differentiate between the indirect promotion of permeabilization with 
AmB model and a direct binding with AmB model. Cholesterol and ent-cholesterol membranes 
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were shown to have similar global membrane properties, so the observed significant differences 
in AmB channel properties between the two membrane systems led to the conclusion that AmB 
directly binds to cholesterol.71  
 
Figure 1.9: Chemical structures of ergosterol derivatives to probe modifications to the side chain. 
 
Figure 1.10: Chemical structures of sterol derivatives to probe modifications to sterol core. 
Recently, modifications to the sterol side chain72 (Figure 1.9) and steroid core73 (Figure 
1.10) were evaluated for their impact on the interaction with AmB via surface plasmon resonance 
(SPR), membrane permeabilization, and SSNMR. On the sterol side chain, the C22-C23 double 
bond and the C24 methyl group of ergosterol were both found to have major roles in its interaction 
with AmB as removal of either group (1.20 and 1.21) resulted in dramatic decreases in binding 
affinity and membrane permeabilization. Furthermore, the sites of unsaturation in the B ring of the 
sterols have a large influence in the binding interaction. Saturation of the C7-C8 double bond 
yielded sterols (1.7 and 1.11) with significantly decreased binding compared to its unsaturated 
counterparts. DFT calculations provided further evidence to the importance of the C7-C8 
unsaturation as the sterol derivatives lacking this double bond have an axial C7 proton that 
sterically hinders the interaction with AmB (Figure 1.11). Collectively, these results have helped 
understand two of the major sites on ergosterol that allow for its strong affinity with AmB over 
other sterols: its unsaturated sterol side chain and the lack of an axial C7 proton. While these 
studies have begun to thoroughly probe the functional groups of the sterols that play major roles 
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in their interaction with AmB, to understand at an atomistic level, a different approach is required 
that is unhindered by covalent modifications.  
 
Figure 1.11: Representative chemical structures and 3D models of AmB’s association with ergosterol and cholesterol based on 
DFT calculations. The axial C7 proton of cholesterol sterically hinders with the polyene of AmB, which may account for the 
selectivity for ergosterol over cholesterol. 
 
1-4 FUNCTIONAL GROUP DELETION STRATEGY TO UNDERSTAND THE ATOMISTIC 
UNDERPINNINGS OF AmB 
 Definitive experiments to understand the mechanistic underpinnings of AmB have been 
challenging. As stated previously, changes in biological and biophysical properties due to covalent 
modification of AmB are complicated by the difficulty of discerning between the loss of a 
functional group moiety or the addition of steric bulk. Due to these complications, the Burke group 
has pursued a different strategy to probe the roles of each protic functional group by systematic 
deletions. This is analogous to alanine scanning74 in peptides and proteins to identify the critical 
residues and the functions they serve.  
 The C41 carboxylate and functional groups on the C19 mycosamine have been 
hypothesized to play major roles in AmB’s activity. In the pursuit of understanding the roles of 
both functional groups, Palacios, et al. synthesized derivatives lacking the C41 carboxylate 
(MeAmB, 1.26), C19 mycosamine (AmdeB, 1.27), or both (MeAmdeB, 1.28) via degradative 
synthesis.75 The ground state conformations of the macrolide were determined to not have changed 
for all three derivatives via Monte Carlo methods constrained by NOESY and phase-sensitive 
COSY NMR,76 which allows for interpretation of any changes in activity from the natural product 
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to be based on simply the functional group deletion as opposed to substantial structural changes. 
Interestingly, MeAmB lacking the C41 carboxylate maintained equipotent antifungal activity as 
the natural product. This is in stark contrast to the prediction that this polar functional group was 
necessary in the biological activity of AmB. Even more interesting, the two derivatives lacking the 
mycosamine sugar were completely devoid of antifungal activity demonstrating that the appendage 
was critical for the antimycotic properties of AmB (Figure 1.12). 
 
Figure 1.12: Chemical structures of AmB derivatives with functional group deletions at the C41 carboxylate, C19 mycosamine, 
or both. Antifungal activity is visualized by the disk diffusion assay where a zone of inhibition can be seen with the active 
compounds AmB and MeAmB. Figure was adapted from reference 75. 
 To further probe this mycosamine-dependent mechanism of action, Palacios, et al. studied 
the biophysical consequences for the deletion of the mycosamine.77 AmdeB and MeAmdeB were 
found to lose the ability to form ion channels in planar lipid bilayer studies19,24 and could no longer 
bind ergosterol via isothermal titration calorimetry (ITC).78 Conversely, the biologically active 
MeAmB, like AmB, still maintained the capacity to bind ergosterol and form ion channels. Based 
on these findings, two possible mechanisms of action could explain AmB’s antifungal activity: 
either sterol-dependent ion channel formation (Figure 1.13A) or the binding of ergosterol alone 
would be enough to kill yeast (Figure 1.13B). However, to differentiate between these two 
mechanisms would require the general access to any desired derivative of AmB to systematically 
probe modifications to AmB and their biological and biophysical consequences. Current AmB 
derivative syntheses involve either covalent modifications or selective degradation, but they are 
limited by the functionalities present in the parent compound. Thus, a general and modular 
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synthesis platform would be highly enabling toward unfettered access of any desired AmB 
analogue.  
 
Figure 1.13: Two mechanisms by which AmB can kill yeast: (A) sterol-dependent ion channel formation or (B) the binding of 
sterol alone is sufficient to kill yeast. 
 
1-5 ITERATIVE CROSS-COUPLING (ICC) AS A GENERAL STRATEGY TOWARD THE 
SYNTHESIS OF SMALL MOLECULES 
 Towards creating a general strategy for the synthesis of complex small molecules, a 
synthesis platform based on iterative cross-coupling (ICC) has been developed.79 In this platform, 
small molecules are constructed by the continual application of the Suzuki-Miyaura reaction with 
bifunctional haloboronic acid building blocks enabled by the attenuation of the reactivity of the 
boronic acid with the N-methyliminodiacetic acid (MIDA) ligand (Figure 1.14). This platform is 
analogous to the iterative synthesis of peptides from amino acid building blocks enabled by the 
amine protecting group, fluorenylmethoxycarbonyl (Fmoc).80  
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Figure 1.14: Iterative cross-coupling (ICC) where small molecules are constructed from N-methyliminodiacetic acid (MIDA) 
boronate building blocks analogous to peptide synthesis with protected amino acids. Figure adapted from Endo, M. M.; Cioffi, A. 
G.; Burke, M. D. Syn. Lett. 2016, 27, 337-354. 
Just as iterative peptide coupling has enabled the synthesis of a wide range of peptides, 
ICC has been utilized toward the synthesis of a number of natural products including ratahine,79,81 
retinal,81,82 parinaric acid,81,82 crocacin C,81,83 peridinin,84 synechoxanthin,85 asnipyrone B,86 
physarigin A,86 neurosporaxanthin β-D-glucopyranoside,86 citreofuran,81 oblongolide,81 and the 
polyene cores of AmB82 and vacidin A.87 In fact, ICC has had a transformative impact on polyene 
synthesis as the polyene cores of over 75% of all polyene natural products can be synthesized from 
just 12 bifunctional MIDA boronate building blocks.86 Furthermore, these MIDA boronates are 
generally free-flowing, air- and temperature-stable, crystalline solids that have an unusual binary 
affinity for silica gel, which has enabled the ICC platform to now be automated.81 This general 
strategy could enable access to any desired AmB derivative by simply changing a single building 
block in this modular platform. 
 
1-6 SUMMARY 
 For over sixty years, AmB has remained as the last line of defense against a wide range of 
invasive fungal infections. Despite its continuous usage and the extensive studies outlined above, 
the mechanism of which AmB kills cells remains unclear. A significant contributor to this lack of 
clarity has been the deficiency of definitive experiments to understand the atomistic underpinnings 
of this complex small molecule. Covalent modifications are the most common strategy in the 
derivatization of AmB. However, interpreting the findings from these derivatives are complicated 
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by the difficulty to discern whether changes in activity are due to functional group changes or 
increases in sterics. Recent studies using functional group-deficient derivatives have found that the 
C19 mycosamine is essential for the biological activity of AmB. However, further work is 
necessary to explore this mycosamine-dependent mechanism of action. The following chapters 
describe the studies taken to understand the mechanism of toxicity to both yeast and human cells 
and how that understanding has enabled the development of less toxic AmB derivatives. 
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CHAPTER 2 
 
ERGOSTEROL BINDING IS THE PRIMARY MECHANISM OF ACTION OF 
AMPHOTERICIN B 
 
 Despite over half a century of study, the primary mechanism of action for AmB has 
remained unclear. We hypothesized that ergosterol binding was the primary mechanism of AmB 
and similarly all mycosamine-containing polyene macrolides. To test this hypothesis, we 
synthesized a derivative of AmB, C35deOAmB, via an iterative cross-coupling (ICC)-based 
strategy. C35deOAmB retained the ability to bind ergosterol, but lacked the capacity to 
permeabilize membranes. This derivative was similar to natamycin, another mycosamine-
containing polyene macrolide, which also binds ergosterol but does not cause membrane 
permeabilization. Both C35deOAmB and natamycin have potent antifungal activities that were 
only six-fold and four-fold less than AmB, respectively. Furthermore, removal of the mycosamine 
appendage from either AmB or natamycin completely abolished the ergosterol binding capacities 
and antifungal activities of both polyene macrolides. These results are consistent with the 
hypothesis that mycosamine-mediated ergosterol binding is the primary mechanism of action for 
mycosamine-containing polyene macrolides, and that the ion channel ability of AmB may act as a 
complementary mechanism that could marginally increase the potency of this natural product. 
 C35deOAmB was prepared in collaboration with Dr. Kaitlyn Gray, Dr. Daniel Palacios, 
Dr. Ian Dailey, Dr. Brice Uno, Dr. Brandon Wilcock, and Prof. Martin Burke. Natamycin aglycone 
was synthesized by Dr. Kaitlyn Gray. ITC experiments were performed in collaboration with Dr. 
Ian Dailey. Liposome and yeast efflux experiments were performed in collaboration with Dr. 
Daniel Palacios. MIC experiments were performed in collaboration with Dr. Daniel Palacios and 
Dr. Kaitlyn Gray. Killing kinetics studies were performed by Dr. Kaitlyn Gray. Ergosterol 
quantification were performed in collaboration with Dr. Daniel Palacios. Portions of this chapter 
were adapted from Gray, K. C.; Palacios, D. S.; Dailey, I.; Endo, M. M.; Uno, B. E.; Wilcock, B. 
C.; Burke, M. D. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 2234-2239. 
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2-1 BACKGROUND 
  As discussed in Chapter 1, despite over half a century of extensive studies, the mechanism 
by which AmB kills yeast remained unclear. However, the recent finding that the deletion of the 
mycosamine appendage resulted in complete abolishment of ergosterol binding capacity, the 
ability to form ion channels, and antifungal activity led us to hypothesize two possible models for 
AmB’s toxicity to yeast.1,2 The first model was the long-standing ion channel model where AmB 
binds to ergosterol and subsequently self-assembles into a transmembrane channel, resulting in 
membrane permeabilization and eventually cell death (Figure 1.1A).3-8 In an alternative model, the 
binding of ergosterol is sufficient for the killing of yeast (Figure 1.1B) and that the ion channel 
capacity only further increases AmB’s potency.  
 Several recent reports found that ergosterol plays a number of critical roles in yeast 
physiology. These include endocytosis,9 pheromone signaling,10 and membrane 
compartmentalization.11 Inhibition of yeast ergosterol biosynthesis by fluconazole also inhibits 
membrane fusion during mating.10 Interestingly, a similar phenomenon occurs when treated with 
the polyene macrolide nystatin.10 Ergosterol is also essential for proper vacuole fusion,12 which 
can be inhibited by natamycin (Figure 2.1C),13 another polyene macrolide that has been shown to 
bind ergosterol but not form ion channels.14 Furthermore, natamycin also inhibits a number of 
membrane transport proteins15 that are highly dependent on ergosterol.16  
 Though incredibly rare, polyene macrolide-resistant yeast strains generally contain 
modified sterol content.17,18 Additionally, structural modification and/or decreased ergosterol 
expression via mutations in the ergosterol biosynthesis pathway dramatically reduces the 
pathogenicity of these yeast strains.19 This may explain the inability for yeast to develop AmB 
resistance in the clinic.20 Collectively, these lines of evidence led us to hypothesize that AmB and 
all other mycosamine-containing polyene macrolides primarily kill yeast by binding membranous 
ergosterol and that capacity to cause membrane permeabilization for certain members only 
marginally increase their potency. 
 
2-2 DESIGN OF PROBES TO TEST ERGOSTEROL BINDING AS THE PRIMARY 
MECHANISM OF AmB 
 In order to test the hypothesis that sterol binding is the primary mechanism of action of 
AmB, we required a derivative of AmB that retains the ability to still bind ergosterol, but lacks the 
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capacity to form ion channels. However, the structures of the AmB/ergosterol complex and the 
multimeric AmB-based ion channel have remained unknown, which makes the rational design of 
such a derivative very challenging. Fortunately, our group's previous studies with AmB had shown 
that mycosamine appendage was critical in AmB ability to bind ergosterol,1,2 so it clear that this 
appendage should remain intact. Alternatively, computer modeling predicted two leading models 
for the AmB ion channel in which both required the C35 hydroxyl group in stabilizing this 
supermolecular ion channel (Figure 1.1A).21 In the single barrel model, the AmB aggregate spans 
a dimpled membrane and the C35 hydroxyl groups form hydrogen bonds with the polar 
phospholipid head groups.21 In the double barrel model, two single barrel units, that each spans 
half the length of the lipid bilayer, dimerize through hydrogen bonds between C35 hydroxyl groups 
of AmB molecules in the opposing membrane leaflets.21 In both cases, the C35 hydroxyl group is 
predicted to play a critical role in AmB's ability to form ion channels and thus would be an 
attractive target towards disrupting AmB's ion channel forming capacity. 
 
Figure 2.1: Mechanisms models and chemical structures of the mechanistic probes. A.) Representation of the single- and double-
barrel ion channel models. B.) Representation of the ergosterol binding model. C.) Chemical structures of the natural products 
AmB, natamycin, and their derivatives to probe the dual mechanism hypothesis. 
 The C35 hydroxyl group has been investigated by Carreira and coworkers by synthesizing 
a doubly-modified derivative of AmB lacking the C35 hydroxyl and where the C41 carboxylate 
was protected as a methyl ester.22,23 This derivative demonstrated a weak potassium efflux from 
liposomes at a concentration of 10 μM and no efflux at a concentration of 1 μM, lending support 
that the C35 hydroxyl plays a major role in ion channel ability. Furthermore, the authors reported 
a 26-fold loss in antifungal activity relative to AmB methyl ester (AmE) against C. albicans. 
However, there was no report of sterol binding for either compound. Based on the liposomal 
potassium efflux assay and antifungal activity, Carreira and coworkers concluded that C35 
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hydroxyl was critical in ion channel formation, which was necessary for the fungicidal activity of 
AmB.23 
 We hypothesized that the weak efflux observed by Carreira and coworkers at elevated 
concentrations was likely an artifact due to the increased sensitivity of liposomes to 
permeabilization compared to live yeast cells and/or the unique biophysical properties of net 
positively-charged AmB derivatives such as the C41 methyl ester derivatives.20 In order to test this 
hypothesis, I performed liposomal potassium efflux assays with AmdeB, which does not bind 
sterol, has no antifungal activity, and does not permeabilize S. cerevisiae even at elevated 
concentrations of 30 μM (Figure 2.2A). While the derivative does not permeabilize yeast cells, it 
does cause potassium efflux in POPC LUVs at 10 and 30 μM (Figure 2.2B), thus demonstrating 
the increased sensitivity of liposomes relative to yeast cells. Additionally, I performed liposomal 
potassium efflux assays with AmE (net positive) compared to AmB (net neutral). Consistent with 
ergosterol being required for AmB ion channel formation, no substantial potassium efflux is 
observed when sterol-free POPC LUVs are treated with AmB even at the elevated concentration 
of 30 μM (Figure 2.3). However, AmE causes significant efflux in sterol-free POPC LUVs at 
concentrations of 10 and 30 μM (Figure 2.3), thus demonstrating the unique biophysical properties 
of net positive AmB derivatives. Thus, toward the goal of retaining sterol binding, abolishing the 
capacity to permeabilize membranes, and enabling the direct comparison in biophysical and 
biological properties with the natural product, we targeted C35deOAmB (Figure 2.1C), which 
retains the C19 mycosamine, lacks the C35 hydroxyl group, and retains the anionic C41 
carboxylate. 
 
Figure 2.2: Potassium efflux upon treatment with AmdeB in (A) S. cerevisiae and (B) POPC LUVs.  
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Figure 2.3: Potassium efflux upon treatment with AmB (net neutral) or AmE (net positive) in sterol-deficient POPC LUVs.  
 To further investigate the generality of mycosamine-dependent sterol binding in polyene 
macrolide natural products, we also targeted the synthesis of natamycin aglycone (Figure 2.1C). 
The methyl ester of this compound had been previously synthesized by Masamune and coworkers 
through degradative synthesis of the natural product.24 Based on that report and our group's 
synthesis of AmdeB, Dr. Kaitlyn Gray completed the synthesis of natamycin aglycone to test the 
hypothesis that mycosamine sugar was critical in the binding of polyene macrolides with 
ergosterol.20 
 
2-3 SYNTHESIS OF C35deOAmB 
 Synthesis of polyene macrolides are very challenging due to their sensitivity to light, 
oxygen, and many organic reagents. To overcome these challenges, we utilized an ICC-based25 
semisynthetic strategy with building blocks 2.5, 2.6, and 2.7 that were linked together via iterative 
Suzuki-Miyaura cross-couplings enabled by the N-methyliminodiacetic acid (MIDA) ligand 
(Figure 2.4). Further details on ICC can be found in Chapter 1. Based on pioneering studies by 
Nicolaou,26-28 Rychnovsky,29 and Murata,30 the synthesis of building block 2.5 was developed by 
Dr. Kaitlyn Gray (Scheme 2.1).20 Large amounts of building block 2.5 were synthesized in 
collaboration with Dr. Daniel Palacios, Dr. Ian Dailey, Dr. Brice Uno, and Dr. Brandon Wilcock. 
Beginning from the natural product, global protection of all of the protic functional groups was 
performed to reach protected intermediate 2.6. The polyene was then excised via ozonolysis, and 
the resulting bisaldehyde was converted to the bisvinyl iodide via Takai olefination. Finally, 
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cleavage of the western half of the bisvinyl iodide followed by cross-coupling with bisborylated 
2.7 yielded our first building block 2.5.  
 
Figure 2.4: Retrosynthesis of C35deOAmB from its three building blocks. 
 
 
Scheme 2.1: Synthesis of building block 2.5. 
 The synthesis of building block 2.6, was previously developed in our group by Dr. Suk 
Joong Lee utilizing the triethylgermanium group as a masking group for halides that could be 
utilized in ICC.31 Due to the need for several grams of building block 2.6, large amounts of building 
block 2.6, were synthesized by Dr. Ian Dailey, Dr. Kaitlyn Gray, and Dr. Brice Uno.20 The 
synthesis of building block 2.7, was developed and prepared by Dr. Kaitlyn Gray.20 
 With all three building blocks in hand, the macrolide skeleton of C35deOAmB was 
assembled by Dr. Kaitlyn Gray and Dr. Ian Dailey (Scheme 2.2).20 Building block 2.5 was 
converted to the pinacol boronic ester, followed by cross-coupling with building block 2.6 yielding 
pentaene 2.10. In situ deprotection of the MIDA boronate and cross-coupling with building block 
2.7, followed by saponification and macrolactonization resulted in 2.11. Global deprotection were 
developed and performed by Dr. Kaitlyn Gray and Dr. Daniel Palacios enabling access to 
C35deOAmB.20 
26 
 
 
Scheme 2.2: Synthesis of C35deOAmB via ICC. 
 
2-4 ERGOSTEROL BINDING VIA ISOTHERMAL TITRATION CALORIMETRY  
 With the desired probes in hand, we first set out to determine the capacity of our 
compounds to bind membrane-embedded ergosterol. In order to study the non-covalent binding of 
our probes and ergosterol, we utilized the valuable technique of isothermal titration calorimetry 
(ITC). ITC is a useful technique for studying the non-covalent interaction between two chemical 
species without having to modify either binding partner and can potentially determine all of the 
thermodynamic parameters of the system in a single experiment.  
 The ITC instrument consists of a sample cell and a reference cell within an adiabatic 
chamber. The sample cells and reference cells are maintained at a constant temperature by applying 
heat to each cell. The instrument measures the difference in heat that is being applied to each of 
the cells. The sample cell is filled with one of the binding partners, in our case, a solution of AmB 
or its derivatives in an aqueous buffer, while the reference cell is filled with aqueous buffer only. 
The syringe contains the other binding partner, which in our case was a suspension of large 
unilamellar vesicles in aqueous buffer, either sterol-containing or sterol-deficient. Using the 
computer software to control the syringe, the suspension is injected into the sample cell in 
controlled amounts. If there is a heat change upon injection, the heat applied to the sample will 
change and the difference in heat applied is measured over time. Integration of this heat difference 
over time results in the enthalpy (ΔH) of this titration system. The titration exotherms can be fitted 
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to a binding model, by which the binding constant (K) and stoichiometry (n) can be determined. 
From these parameters, the remaining thermodynamic parameters, free energy (ΔG) and entropy 
(ΔS), can also be determined. 
 Our group2 as well as the te Welscher group14 have previously utilized ITC to study polyene 
macrolides binding to membrane-embedded sterols. However, due to significant synthetic 
overhead to generate C35deOAmB, we needed to minimize the amount of compound used in the 
ITC experiment without compromising the sensitivity of the experiment. Our group had originally 
used a MicroCal calorimeter with a sample cell volume of 1.45 mL, but actually required 2.2 mL 
of sample solution for sample loading.2 The concentration used in these experiments was 150 μM, 
and so a single ITC experiment required almost 300 μg of material. In collaboration with Dr. Ian 
Dailey, we sought to miniaturize the ITC assay using a NanoITC calorimetry that had a sample 
cell volume of just 190 μL, which required 300 μL of sample solution.20 We were able to reduce 
our required sample amount by almost tenfold (~40 μg), enabling the completion of this study. 
 
Figure 2.5: Isothermal titration calorimetry with all five probes titrated with 10% ergosterol-containing or sterol-free LUVs. * P ≤ 
0.05, ** P ≤ 0.01, and NS = not significant. 
 To validate our new ITC conditions, we first titrated AmB with either sterol-free or 10% 
ergosterol-containing POPC LUVs (Figure 2.5). Consistent with our previous results,2 a 
substantial increase in net exotherm was observed when titrating with ergosterol-containing LUVs 
compared to sterol-deficient LUVs, indicating a direct binding interaction between AmB and 
ergosterol. We performed the same set of experiments with AmdeB and observed no change in 
exotherm when titrating with ergosterol-containing LUVs compared to sterol-free LUVs, again 
consistent with previous results that the mycosamine appendage is required for AmB to bind 
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ergosterol.2 With our validated miniaturized ITC assay, we performed the same series of 
experiments with natamycin and its aglycone. Consistent with literature precedent,14 we observed 
a significant increase in exotherm when titrating with 10% ergosterol-containing POPC LUVs 
relative to sterol-free POPC LUVs, demonstrating that natamycin binds ergosterol. However, 
natamycin aglycone showed no difference in exotherm between the two LUV systems, 
demonstrating for the first time that the mycosamine sugar was critical for natamycin to bind 
ergosterol. This provided further evidence for the hypothesis that the mycosamine appendage was 
a universal sterol binding element in polyene macrolides. Most importantly, we titrated 
C35deOAmB with our two LUVs system and observed an increase in exotherm identical to that 
of AmB, indicating that C35deOAmB retains its capacity to bind ergosterol.    
 
2-5 MEMBRANE PERMEABILIZATION 
 Having determined the capacities for our probes to bind ergosterol, we next investigated 
their abilities to permeabilize membranes. In collaboration with Dr. Daniel Palacios, we developed 
a potassium ion efflux assay to test our probes' capacities to permeabilize lipid and yeast 
membranes. In this assay, we would take a suspension of the same 10% ergosterol-containing 
POPC LUVs from our ITC studies or S. cerevisiae cells in a potassium-free buffer and add our 
small molecule probes. The extracellular potassium concentration would be measured with a 
commercially available valinomycin-based potassium-selective ion probe. 
 Our group had previously used an electromagnetic-shielded potassium-selective ion probe 
to detect extracellular efflux of potassium.2 However, the bulkiness of this shielded potassium ion 
probe required 15 mL of a 30 μM solution of our small molecule probes in this assay, which would 
be ~400 μg per experiment. Due to the synthetic overhead of our C35deOAmB probe, we once 
again sought to minimize the assay with a smaller unshielded potassium-selective probe. With this 
smaller probe, we were able to minimize the volume to 3 mL of a 30 μM solution for a five-fold 
(~80 μg) reduction. However, this unshielded potassium ion probe was subject to electromagnetic 
interference and so the assay set-up was placed in a Faraday cage to minimize undesired 
interference.  
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Figure 2.6: Potassium efflux in (A) 10% ergosterol-containing POPC LUVs and (B) live S. cerevisiae upon treatment with all five 
probes. 
 With our miniaturized potassium efflux assay, we first tested our molecular probes' 
capacities to permeabilize the lipid membranes of the same 10% ergosterol-containing POPC 
LUVs that we used in ITC experiments (Figure 2.6A). Exposure of the LUVs to AmB at a 
concentration of 1 μM produced a rapid efflux of potassium ions. In contrast, administration of 
AmdeB, natamycin, and natamycin aglycone showed no potassium efflux, demonstrating that 
these compounds do not permeabilize membranes. Importantly, C35deOAmB was devoid of 
permeabilizing activity, even at the relatively high concentration of 10 μM. We then examined the 
ability of our probes to permeabilize live S. cerevisiae cells (Figure 2.6B). AmB, at 3 μM, produced 
a rapid and robust efflux of potassium ions from the yeast cells, whereas AmdeB, natamycin, and 
natamycin aglycone did not, lacking the capacity to cause membrane permeabilization. Most 
importantly, C35deOAmB also was devoid of membrane permeabilization, even at the high 
concentration of 30 μM. Collectively, these results demonstrate that C35deOAmB retains the 
ability to bind ergosterol, but lacks the capacity for membrane permeabilization. This derivative is 
a powerful tool for probing our hypothesis that sterol binding is primary mechanism of action for 
the antifungal activity of AmB. Furthermore, the loss in sterol binding capacity for AmdeB and 
natamycin aglycone provide further evidence of the putatively dominant and general role of the 
mycoamine appendage in the antifungal activity of polyene macrolide natural products.  
 
2-6 ANTIFUNGAL ACTIVITY 
 In collaboration with Dr. Daniel Palacios and Dr. Kaitlyn Gray, we examined the ability of 
our derivatives to kill S. cerevisiae cells in standardized broth microdilution assays (Figure 2.7A). 
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AmB, which binds ergosterol and forms ion channels, showed potent antifungal activity with a 
minimum inhibitory concentration (MIC) of 0.5 μM. AmdeB, the non-sterol binding aglycone, 
was completely inactive against S. cerevisiae even up to 500 μM.1,2 Natamycin, which binds 
ergosterol but does not form ion channels, was just four-fold less potent than AmB (MIC = 2 μM). 
Like AmdeB, natamycin aglycone was also completely inactive up to 500 μM. Most importantly, 
C35deOAmB still maintained antifungal activity (MIC = 3 μM). Interestingly, both natamycin and 
C35deOAmB, which bind ergosterol but lack the capacity to permeabilize membranes, have 
remarkably similar MICs. We tested our probes against the clinically relevant yeast C. albicans 
and observed a very similar set of results. 
 
Figure 2.7: Yeast toxicity assays (A) MICs from microbroth dilution assays of all five probes. Killing kinetics studies with (B) S. 
cerevisiae and (C) C. albicans where AmB and C35deOAmB demonstrate potent fungicidal activity in contrast to the known 
fungistatic agent ketoconazole. 
 To further probe whether ergosterol binding was a fungicidal or fungistatic mode of action, 
Dr. Kaitlyn Gray performed yeast killing kinetics studies to differentiate between both modes in 
S. cerevisiae (Figure 2.7B).32 AmB showed a dramatic decrease in colony forming units (CFUs) 
below the limit of detection, consistent with AmB being a known fungicidal agent. While 
ketoconazole, a known fungistatic agent, maintained the number of CFUs across the 24 hour study. 
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Most importantly, C35deOAmB causes a significant decrease in CFUs, providing evidence that 
ergosterol binding is a fungicidal mechanism of action. A similar set of results was also seen in C. 
albicans (Figure 2.7B).  
 Finally, the hypothesis that ergosterol binding is the primary mechanism of action would 
predict that there would be a significant number of AmB molecules relative to ergosterol molecules 
at the MIC. To test this hypothesis, in collaboration with Dr. Daniel Palacios, we quantified the 
number of ergosterol molecules in a yeast cell at the MIC via extraction and high performance 
liquid chromatography (HPLC) quantification (Figure 2.8).33 Acidic and alkaline reflux disrupted 
the membrane integrity, which enabled extraction of the ergosterol from the lysed yeast cells. The 
amount of ergosterol extracted was compared to a standard curve via HPLC analysis. We found 
that at the MIC, there is over a magnitude greater amount of AmB molecules per a yeast cell 
compared to the number of ergosterol molecules per a yeast cell in both S. cerevisiae and C. 
albicans. 
 
Figure 2.8: Quantification of the number of molecules of ergosterol per yeast cell compared to the number of AmB molecules per 
yeast cell at the MIC concentration. 
 Collectively, these results strongly support the hypothesis that mycosamine-mediated 
ergosterol binding is the primary mechanism of action of AmB and that its ion channel formation 
ability is a complementary mechanism that further increases the potency of this natural product.20 
Furthermore, the conservation of the mycosamine sugar in the large family of polyene macrolides 
combined with the requirement for this moiety to bind ergosterol highly suggests that mycosamine-
mediated ergosterol binding is the primary antifungal mechanism of action across this entire family 
of natural products.  
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2-7 SUMMARY 
 Utilizing the ICC platform,25 we have completed the synthesis of C35deOAmB and with 
this probe, determined the primary mechanism of action for mycosamine-containing polyene 
macrolides. C35deOAmB retains the ability to bind ergosterol, but is unable to permeabilize 
membranes similar to natamycin, another polyene macrolide. Despite the loss in capacity for 
membrane permeabilization, both natamycin and C35deOAmB demonstrate similar potent 
antifungal activity. Removal of the mycosamine sugar from AmB and natamycin completely 
abolishes sterol binding ability and antifungal activity for both polyene macrolides. These results 
strongly support the conclusion that mycosamine-mediated sterol binding is the primary 
mechanism of action of mycosamin-containing polyene macrolides. This finding has important 
implications in several areas. 
 First, the rapid development of antibiotic resistance has resulted in an emergent global 
public health crisis.34-36 However, despite its extensive use for over half a century, AmB resistance 
has remained exceptionally rare.37,38 Thus, clinically relevant antimicrobial mechanisms that evade 
resistance exist, and include AmB’s mode(s) of action. The discovery that AmB acts primarily by 
binding a functionally vital lipid suggests that this may represent a mechanism of action with the 
potential to evade resistance in the clinical setting. Additionally, the possession of a dual mode of 
action, i.e., lipid binding and membrane permeabilization, likely contributes to AmB's resistance-
refractory nature. This dual mechanism property is shared with the antimicrobial peptide nisin that 
also operates primarily by binding the critically vital Lipid II in bacterial membranes and 
secondarily promotes membrane permeabilization.39  
 Second, the discovery that ergosterol binding rather than ion channel formation is the 
primary mechanism of action of AmB suggests that the cytocidal effects of these two mechanisms 
may be separable. This has important implications for the development of small molecules that 
can replace the function of missing or deficient ion channel proteins in human disease. The 
discovery that membrane permeabilization is a relatively minor contributor to the cytocidal activity 
has led to the recent discovery that this achievable as AmB has been utilized to restore the 
physiology of a yeast strain missing a critical protein ion channel.40 
 Finally, extensive efforts to improve the therapeutic index of AmB has been guided by the 
classic mechanistic model in which ion channel formation is paramount to its biological activity.3-
8 These studies have focused on selectively forming ion channels in yeast cells versus human cells. 
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However, the discovery that ergosterol binding is the primary mechanism for its fungicidal activity 
against yeast suggests that cholesterol binding may be the primary mechanism of toxicity in 
humans. If that is case, improving the therapeutic index of AmB can focus on the much simpler 
problem of selectively binding ergosterol over cholesterol. 
 
2-8 EXPERIMENTAL SECTION 
Materials.  
Commercially available materials were purchased from Sigma-Aldrich, Alfa Aesar, Strem, 
Avanti Polar Lipids, or Fisher Scientific and were used without further purification unless stated 
otherwise. Amphotericin B was a generous gift from Bristol-Myers Squibb Company. All solvents 
were dispensed from a solvent purification system that passes solvents through packed columns 
according to the method of Pangborn and coworkers41 (THF, Et2O, CH2Cl2, toluene, dioxane, 
hexanes : dry neutral alumina; DMSO, DMF, CH3OH : activated molecular sieves). Water was 
obtained from a Millipore MilliQ water purification system.  
 
Reactions.  
All reactions were performed in oven- or flame-dried glassware under an atmosphere of 
argon unless otherwise indicated. Reactions were monitored by analytical thin layer 
chromatography performed using the indicated solvent on E. Merck silica gel 60 F254 plates 
(0.25mm). Compounds were visualized using a UV (λ254) lamp or stained by an acidic solution of 
KMnO4.  
 
Purification and Analysis.  
Flash chromatography was performed as described by Still and coworkers42 using the 
indicated solvent on E. Merck silica gel 60 230-400 mesh. 1H NMR spectra were recorded at 23 °C 
on one of the following instruments: Varian Unity 400, Varian Unity 500, Varian Unity Inova 
500NB. Chemical shifts (δ) are reported in parts per million (ppm) downfield from 
tetramethylsilane and referenced internally to the residual protium in the NMR solvent (CHCl3, δ 
= 7.26) or to added tetramethylsilane. 13C spectra were recorded at 23 °C with a Varian Unity 500. 
Chemical shifts (δ) are reported downfield of tetramethylsilane and are referenced to the carbon 
resonances in the NMR solvent (CDCl3, δ = 77.16, center line) or to added tetramethylsilane. High 
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resolution mass spectra (HRMS) were obtained at the University of Illinois mass spectrometry 
facility. All synthesized compounds gave HRMS within 5 ppm of calculated values.  
 
 
Acetal Protected 2.12 
 Trimethyl acetyl chloride (400 μL, 3.25 mmol, 2 eq) was added to a solution of phenyl 
acetic acid (662 mg, 4.86 mmol, 3 eq) in THF (30 mL). Triethylamine (900 μL, 6.46 mmol, 4 eq) 
was added to the reaction, and it was stirred for 6 hours at 23 C. The reaction was placed in an 
ice bath, and DMSO (30 mL) was added over 2 minutes as the solution cooled. Once the reaction 
mixture reached 0 °C, AmB (1.50 g, 1.62 mmol, 1 eq) was added. The yellow-tan suspension was 
stirred for 90 minutes at 0 °C. The reaction was then poured into diethyl ether (1.8 L) with rapid 
stirring. After 15 minutes of stirring, the resulting yellow precipitate was vacuum filtered and 
washed 3 times with diethyl ether (200 mL). The yellow powder was placed under vacuum for 8 
hours prior to the next reaction. 
Three 1.5 gram batches of N-phenyl acyl amphotericin B were pooled together for the 
succeeding reactions. The yellow solid (5.00 g, 4.80 mmol, 1 eq) was dissolved in a mixture of 
methanol (90 mL, 0.05 M) and THF (90 mL) and the solution was cooled to 0 C. () 
Camphorsulfonic acid (223 mg, 0.96 mmol, 0.2 eq) was added to the cooled solution and the 
reaction was stirred for one hour at 0 C. The reaction was quenched at 0 C with triethylamine 
(130 L, 0.96 mmol, 0.2 eq) and the volume of the solvent was reduced in vacuo by approximately 
50 percent. The solution was poured into 3.6 L of a 1:1 ether:hexane solution and the resulting 
precipitate was isolated via vacuum filtration. The yellow solid was taken forward to the next step 
without further purification.  
The yellow solid (ca 5 g, 4.8 mmol, 1 eq) was dissolved in methanol (80 mL) and p-
anisaldehyde methyl acetal (12 mL, 70 mmol, 146 eq) was added to the reaction. Subsequently, 
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() camphorsulfonic acid (449 mg, 1.93 mmol, 0.4 eq) was added and the reaction was stirred at 
23 C for one hour. The reaction was quenched by the addition of triethylamine (270 L, 1.92 
mmol, 0.4 eq) and the solvent was removed in vacuo. The crude was purified via flash 
chromatography (SiO2; 3%  10% MeOH/DCM/0.15 AcOH) to yield 2.12 as an orange solid 
(3.20 g, 2.48 mmol, 52% over three steps) of approximately 70% purity which was carried forward 
without further purification. 
 
 
TLC (10% MeOH/DCM/0.1% AcOH) 
 Rf = 0.15 stained by anisaldeyde. 
1H NMR (500 MHz, acetone-d6) 
δ 7.42 (d, J = 8.5 Hz, 2H), 7.34 (d, J = 8.5 Hz, 4H), 7.27 (t, J = 7.5 Hz, 2H), 7.22 (app. t, J 
= 7.5 Hz, 1H), 6.86 (dd, J = 3.0, 9.0 Hz, 4H), 6.44-6.19 (m, 12H), 5.87 (dd, J = 5.5, 15.0 
Hz, 1H), 5.56 (dd, J = 9.5, 13.5 Hz, 1H), 5.51 (s, 1H), 5.46 (s, 1H), 5.28-5.25 (m, 1H), 4.67 
(app. t, J = 6.0 Hz, 1H), 4.61 (s, 1H), 4.24-4.09 (m, 3H), 3.96-3.84 (m, 4H), 3.77 (s, 6H), 
3.65 (s, 2H), 3.44-3.42 (m, 1H), 3.38-3.29 (m, 3H), 3.04 (s, 3H), 2.57 (dd, J = 6.0, 16.5 Hz, 
1H), 2.42-2.37 (m, 1H), 2.32-2.27 (m, 2H), 2.21 (app. t, J = 10.0 Hz, 1H), 2.16-2.10 (m, 
1H), 1.89-1.81 (m, 3H), 1.76-1.63 (m, 4H), 1.56-1.43 (m, 4H), 1.36-1.27 (m, 3H), 1.21 (d, 
J = 5.5 Hz, 3H), 1.18 (d, J = 6.0 Hz, 3H), 1.10 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 7.5 Hz, 3H). 
13C NMR (125 MHz, acetone-d6) 
 169.8, 160.6, 160.5, 136.9, 134.2, 133.8, 133.0, 132.9, 132.7, 132.6, 130.1, 129.1, 128.3, 
128.2, 127.3, 113.9, 101.1, 100.8, 100.6, 97.9, 81.1, 76.4, 74.4, 73.2, 72.9, 70.7, 70.5, 67.2, 
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67.0, 57.2, 56.4, 55.5, 48.7, 43.6, 43.3, 41.5, 37.9, 34.0, 33.3, 18.9, 18.2, 17.6, 11.9. 
HRMS (ESI) 
 calculated for C72H93NO20 (M+Na)+:   1314.6189 
 found:       1314.6213 
 
TBS Protected 4.59 
 Prior to the reaction, 2.12 was coevaporated with acetonitrile (3 x 25 mL) and left under 
vacuum for a minimum of eight hours. The resulting orange solid (2.98 g, 2.31 mmol, 1 eq) was 
dissolved in dichloromethane (70 mL) and 2,6-lutidine (3.5 mL, 30 mmol, 13 eq) was added to the 
solution. The reaction was subsequently cooled to 0 C and tert-butyldimethylsilyl trifluromethane 
sulfonate (5 mL, 22 mmol, 9.5 eq) was added dropwise over approximately 15 minutes. The 
reaction was stirred for 1 hour at 0 C and was then quenched by the addition of 50 mL saturated 
aqueous sodium bicarbonate. The biphasic mixture was transferred to a 2 L separatory funnel and 
was diluted with diethyl ether (1 L). The layers were separated and the organic phase was washed 
with saturated aqueous sodium bicarbonate (1 x 100 mL) and water (1 x 100 mL). The combined 
aqueous washings were back-extracted with diethyl ether (1 x 50 mL) and the combined organic 
extracts were washed with saturated aqueous copper sulfate (5 x 100 mL). The combined copper 
sulfate washings were back-extracted with diethyl ether (1 x 100 mL) and the combined organic 
extracts were washed with water (1 x 100 mL) and brine (1 x 100 mL), dried over sodium sulfate 
and concentrated in vacuo.  
The resulting brown oil was taken up in THF:MeOH:H2O (70 mL, 3:1:1 v/v/v) and 
potassium carbonate (3.2 g, 23 mmol, 10 eq) was added. Within approximately five minutes the 
reaction transitioned from turbid to clear. The reaction was stirred for 30 minutes at 23 C and was 
then quenched by the addition of 50 mL potassium phosphate buffer (50 mL, pH 7.0). The mixture 
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was transferred to a 1 L separatory funnel and was extracted with diethyl ether (3 x 250 mL). The 
combined organic extracts were dried over sodium sulfate and concentrated in vacuo. The crude 
was purified via flash chromatography (SiO2; 30%  100% EtOAc) to yield the title compound 
2.13 as a yellow solid (1.21 g, 0.65 mmol, 28%). 
 
TLC (30% EtOAc/hexanes) 
Rf  = 0.2 stained by anisaldehyde. 
1H NMR (500 MHz, acetone-d6)  
 7.39 (d, J = 8.5 Hz, 2H), 7.37-7.27 (m, 4H), 7.24-7.22 (m, 1H), 6.98 (d, J = 7.5 Hz, 1H), 
6.87-6.84 (m, 4H), 6.50 (d, J = 9 Hz, 1H), 6.44-6.30 (m, 8H), 6.28-6.18 (m, 2H), 6.06 (dd, 
J = 10, 15 Hz, 1H), 5.81 (dd, J = 6, 15 Hz, 1H), 5.66 (dd, J = 9.5, 15 Hz, 1H), 5.45 (s, 2H) 
4.85 (bs, 1H), 4.66 (app t, 6 Hz, 1H), 4.58 (s, 1H), 4.25 (dt, 4.5, 10.5 Hz, 1H), 4.21-4.16 
(m, 1H), 4.01-3.91(m, 2H), 3.92-3.87 (m, 3H), 3.79 (s, 3H), 3.71 (s, 3H), 3.71-3.69 (m, 
1H), 3.60 (s, 3H), 3.58-3.55 (m, 1H), 3.42-3.37 (m, 2H), 3.05 (s, 3H), 2.52 (dd, J = 7.5, 
17.5 Hz, 1H), 2.41 (s, 2H), 2.27 (d, J = 5 Hz 1H), 2.28 (t, 3.5 Hz, 1H), 2.25-2.23 (m, 1H), 
2.11 (dd, J = 4, 12 Hz, 1H), 1.92-1.84 (m, 2H), 1.73-1.69 (m, 1H), 1.66-1.61 (m, 1H), 1.59-
1.47 (m, 2H), 1.44-1.40 (m, 1H), 1.34-1.27 (m, 2H), 1.23 (d, J = 6.5 Hz, 3H), 1.18 (d, J = 
6 Hz, 3H), 1.16-1.15 (m, 1H), 1.00 (d, J = 7 Hz, 3H), 0.95 (d, J = 7 Hz, 3H), 0.928, (s, 9H), 
0.899 (s, 9H), 0.865 (s, 9H), 0.845 (s, 9H), 0.757 (s, 9H), 0.120 (s, 3H), 0.114 (s, 3H), 
0.108 (s, 3H), 0.098 (s, 3H), 0.073 (s, 3H), 0.071 (s, 3H), 0.059 (s, 3H), 0.029 (s, 3H), -
0.044, (s, 3H), -0.054 (s, 3H), -0.134 (s, 3H). 
13C NMR (125 MHz, acetone-d6) 
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 173.5, 170.2, 169.4, 160.1, 160.0, 157.5, 135.6, 134.1, 133.8, 133.2, 132.9, 132.5, 132.1, 
132.0, 131.1, 130.6, 129.8, 129.7, 128.6, 128.1, 127.9, 127.8, 127.7, 120.4, 120.3, 113.4, 
113.3, 101.0, 100.8, 100.6, 100.4, 100.2, 97.6, 75.5, 74.4, 73.0, 72.8, 72.3, 68.2, 67.0, 56.7, 
56.0, 55.0, 54.9, 54.8, 43.2, 40.7, 26.2, 26.18, 26.05, 25.99, 25.91, 25.79, 25.72, 25.60, 
25.40, 23.80, 18.44, 18.30, 18.11, 17.87, -3.65, -3.75, -3.93, -4.27, -4.42,-4.54, -4.63, -4.80, 
-5.22. 
HRMS (ESI) 
calculated for C102H163NO20Si5 (M + Na)+:   1885.0513 
found :               1885.0470 
 
 
Trimethylsilyl ethyl ester 4.45 
A 200 mL round bottom flask was charged with penta tert-butyldimethyl silyl 4.59 (1.2 g, 0.61 
mmol, 1 eq) and THF (35 mL) was added. The solution was cooled to 0 C and 2-(trimethylsilyl) 
ethanol (0.28 mL, 1.9 mmol, 3 eq) was added followed by triphenylphosphine (420 mg, 1.6 mmol, 
2.5 eq). The reaction was stirred at 0 C for approximately 10 minutes and then diisopropyl 
azodicarboxylate (0.28 mL, 1.4 mmol, 2.2 eq) was added dropwise. The reaction was then 
transferred to a 45 C water bath and was stirred for 2 hours. After 2 hours the reaction was 
concentrated in vacuo and was subsequently dissolved in hexanes (100 mL). The hexanes solution 
was stirred for 10 minutes, the resulting precipitate was removed via vacuum filtration and the 
filtrate was concentrated in vacuo. The crude was purified via flash chromatography (SiO2; 0%  
20% EtOAc/hexanes) to yield the trimethylsilyl ethyl ester 4.45 as yellow foamy solid (1.06 g, 
0.539 mmol, 84%).  
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TLC (20% EtOAc/hexanes) 
Rf  = 0.32, stained by anisaldehyde. 
1H NMR (500 MHz, acetone d6) 
 7.38 (d, J = 8.5 Hz, 2H), 7.37-7.27 (m, 6H), 7.23-7.20 (m, 1H), 6.87-6.83 (m, 4H), 6.42-
6.30 (m, 9H), 6.25-6.18 (m, 2H), 6.07 (dd, J = 10, 15.5 Hz, 1H), 5.80 (dd, J = 6.5, 14.5 Hz, 
1H), 5.67 (dd J = 9.5, 15.5 Hz, 1H) 5.45 (s, 2H), 4.86 (bs, 1H), 4.61 (app t J = 7 Hz, 1H), 
4.57 (s, 1H), 4.24-4.15 (m, 4H), 4.02 (dt, J = 2, 6 Hz, 1H), 3.93-3.92 (m, 2H), 3.89-3.85 
(m, 3H), 3.78 (s, 3H), 3.77 (s, 3H), 3.75-3.71 (m, 2H), 3.57 (s, 3H), 3.41-3.37 (m, 3H), 
3.06 (s, 3H), 2.52 (dd, J = 7.5, 17.5 Hz, 1H), 2.44-2.40 (m, 1H), 2.31 (app t, J = 9.5 Hz, 
1H), 2.28-2.24 (m, 3H), 2.00-1.95 (m, 1H), 1.89-1.85 (m, 1H), 1.81 (dd, J = 6.5, 13.5 Hz, 
1H), 1.72-1.69 (m, 1H), 1.65-1.60 (m, 2H), 1.54-1.50 (m, 1H), 1.45-1.43 (app d, J = 12.5 
Hz, 1H), 1.23 (d, J  = 6 Hz, 3H), 1.21-1.20 (m, 1H), 1.18 (d, J = 9.5 Hz, 3H), 1.01 (app t, 
J = 7 Hz, 1H), 1.06-1.04 (m, 1H), 1.01 (d, J = 6.5 Hz, 3H), 0.940 (d, J = 7 Hz, 3H), 0.928 
(s, 9H), 0.916-0.912 (m, 1H), 0.900 (s, 9H), 0.888-0.885 (m, 1H), 0.864 (s, 9H), 0.842 (s, 
9H), 0.749 (s, 9H), 0.118 (s, 3H), 0.107 (s, 3H), 0.099 (s, 3H), 0.069 (s, 3H), 0.055 (s, 9H), 
0.038 (s, 3H), 0.020 (s, 3H), -0.002 (s, 3H), -0.046 (s, 3H), -0.084 (s, 3H), -0.169 (s, 3H).  
13C NMR (125 MHz, acetone-d6) 
 172.7, 169.5, 169.4, 160.1, 160.0, 136.2, 135.7, 134.1, 133.7, 133.2, 133.1, 132.8, 132.5, 
132.3, 132.1, 132.0, 130.6, 129.7, 128.5, 128.0, 127.7, 126.9, 113.4, 101.0, 100.5, 100.2, 
98.1, 80.6, 75.4, 75.3, 74.3, 74.2, 72.9, 72.5, 72.3, 68.4, 67.2, 62.8, 58.8, 56.5, 55.8, 55.0, 
54.9, 54.8, 47.9, 43.5, 42.8, 40.8, 37.4, 36.2, 32.8, 32.2, 27.5, 27.4, 26.1, 26.0, 25.9, 25.6, 
25.3, 21.9, 21.8, 21.7, 19.3, 18.5, 18.3, 18.1, 17.9, 17.8, 17.7, -1.51, -1.72, -2.01, -3.73, -
3.77, -3.93, -4.28, -4.38, -4.49, -4.62, -4.74, -5.33. 
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HRMS (ESI) 
calculated for C107H175NO20Si6 (M + Na)+:  1985.1221 
found:       1985.1249 
 
Isothermal Titration Calorimetry 
General Information. 
Experiments were performed using a NanoITC isothermal titration calorimeter (TA 
Instruments, Wilmington, DE). Solutions of the compounds to be tested were prepared by diluting 
a 15.0 mM stock solution of the compound in DMSO to 150 M with K buffer (5.0 mM 
HEPES/KHEPES, 150 mM KCl, pH = 7.4). The final DMSO concentration in the solution was 
1% v/v. POPC LUVs were prepared and phosphorus and ergosterol content was quantified as 
described below. The LUV solutions were diluted with buffer and DMSO to give a final 
phospholipid concentration of 8.0 mM in a 1% DMSO/K buffer solution. Immediately prior to use, 
all solutions were degassed under vacuum at 20 °C for 10 minutes. The reference cell of the 
instrument (volume = 0.190 mL) was filled with a solution of 1% v/v DMSO/K buffer. 
 
LUV Preparation.  
Palmitoyl oleoyl phosphatidylcholine (POPC) was obtained as a 20 mg/mL solution in 
CHCl3 from Avanti Polar Lipids (Alabaster, AL) and was stored at -20 C under an atmosphere of 
dry argon and used within 1 month. A 4 mg/mL solution of ergosterol in CHCl3 was prepared 
monthly and stored at 4 C under an atmosphere of dry argon. Prior to preparing a lipid film, the 
solutions were warmed to ambient temperature to prevent condensation from contaminating the 
solutions. A 13 x 100 mm test tube was charged with 1.2 mL POPC and 350 L of the ergosterol 
solution. For sterol-free liposomes, a 13 x 100 mm test tube was charged with 1.2 mL POPC. The 
solvent was removed with a gentle stream of nitrogen and the resulting lipid film was stored under 
high vacuum for a minimum of eight hours prior to use. The film was then hydrated with 1 mL of 
5 mM K buffer and vortexed vigorously for approximately 3 minutes to form a suspension of 
multilamellar vesicles (MLVs). The resulting lipid suspension was pulled into a Hamilton (Reno, 
NV) 1 mL gastight syringe and the syringe was placed in an Avanti Polar Lipids Mini-Extruder. 
The lipid solution was then passed through a 0.20 μm Millipore (Billerica, MA) polycarbonate 
filter 21 times, the newly formed large unilamellar vesicle (LUV) suspension being collected in 
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the syringe that did not contain the original suspension of MLVs to prevent the carryover of MLVs 
into the LUV solution.  
 
Determination of Phosphorus Content.  
Determination of total phosphorus was adapted from the report of Chen and coworkers.43 
Three 10 μL samples of the LUV suspension were added to three separate 7 mL vials. Subsequently, 
the solvent was removed with a stream of N2. To each dried LUV film, and a fourth vial containing 
no lipids that was used as a blank, was added 450 μL of 8.9 M H2SO4. The four samples were 
incubated open to ambient atmosphere in a 225 °C aluminum heating block for 25 min and then 
removed to 23 °C and cooled for 5 minutes. After cooling, 150 μL of 30% w/v aqueous hydrogen 
peroxide was added to each sample, and the vials were returned to the 225 °C heating block for 30 
minutes. The samples were then removed to 23 °C and cooled for 5 minutes before the addition of 
3.9 mL water. Then 500 μL of 2.5% w/v ammonium molybdate was added to each vial and the 
resulting mixtures were then vortexed briefly and vigorously five times. Subsequently, 500 μL of 
10% w/v ascorbic acid was added to each vial and the resulting mixtures were then vortexed briefly 
and vigorously five times. The vials were enclosed with a PTFE lined cap and then placed in a 
100 °C aluminum heating block for 7 minutes. The samples were removed to 23 °C and cooled for 
approximately 15 minutes prior to analysis by UV/Vis spectroscopy. Total phosphorus was 
determined by observing the absorbance at 820 nm and comparing this value to a standard curve 
obtained through this method and a standard phosphorus solution of known concentration. 
 
Determination of Ergosterol Content.  
Ergosterol content was determined spectrophotometrically. A 50 μL portion of the LUV 
suspension was added to 450 μL 2:18:9 hexane:isopropanol:water (v/v/v). Three independent 
samples were prepared and then vortexed vigorously for approximately one minute. The solutions 
were then analyzed by UV/Vis spectroscopy and the concentration of ergosterol in solution was 
determined by the extinction coefficient of 10400 L mol-1 cm-1 at the UVmax of 282 nm and was 
compared to the concentration of phosphorus to determine the percent sterol content. The 
extinction coefficient was determined independently in the above ternary solvent system. LUVs 
prepared by this method contained between 7 and 14% ergosterol.  
 
42 
 
Titration Experiment. 
Titrations were performed by injecting the LUV suspension at ambient temperature into 
the sample cell (volume = 0.191 mL) which contained the 150 M solution of the compound in 
question at 25 °C. The volume of the first injection was 0.23 μL. Consistent with standard 
procedure,44 due to the large error commonly associated with the first injection of ITC experiments, 
the heat of this injection was not included in the analysis of the data. Next, nineteen 2.52 L 
injections of the LUV suspension were performed. The spacing between each injection was 240 
seconds to ensure that the instrument would return to a stable baseline before the next injection 
was made. The rate of stirring for each experiment was 300 rpm.  
 
Data Analysis. 
NanoAnalyze software (TA Instruments) was used for baseline determination and 
integration of the injection heats, and Microsoft Excel was used for subtraction of dilution heats 
and the calculation of overall heat evolved. To correct for dilution and mixing heats, the heat of 
the final injection from each run was subtracted from all the injection heats for that particular 
experiment.45 By this method, the overall heat evolved during the experiment was calculated using 
the following formula: 
)(μcal
1



n
i
n
injection
i
injectionoverall hh  
Where i = injection number, n = total number of injections,

hinjection
i
 = heat of the ith injection, and 

hinjection
n
 = the heat of the final injection of the experiment. Values represent the mean ± SD of at 
least three experiments. 
 
Potassium Efflux Assays 
General Information. 
 Ion selective measurements were obtained using a Denver Instruments (Denver, CO) 
Model 225 pH meter equipped with a World Precision Instruments (Sarasota, FL) potassium 
selective electrode inside a Faraday cage. The electrode filled with 1000 ppm KCl standard 
solution and conditioned in a 1000 ppm KCl standard solution for 30 minutes prior to ion selective 
measurements. Measurements were made on 3 mL solutions that were magnetically stirred in 7 
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mL Wheaton vials incubated in a 30 °C aluminum block (S. cerevisiae) or at 23 °C (LUVs). The 
instrument was calibrated daily with KCl standard solutions to 10, 100, and 1000 ppm potassium. 
The potassium concentration was sampled every 30 seconds throughout the course of the efflux 
experiments.  
 
Growth Conditions for S. cerevisiae.  
 S. cerevisiae was maintained with yeast peptone dextrose (YPD) growth media consisting 
of 10 g/L yeast extract, 20 g/L peptone, 20 g/L dextrose, and 20 g/L agar for solid media. The 
media was sterilized by autoclaving at 250 °F for 30 min.  Dextrose was subsequently added as a 
sterile 40% w/v solution in water (dextrose solutions were filter sterilized). Solid media was 
prepared by pouring sterile media containing agar (20 g/L) onto Corning (Corning, NY) 100 x 20 
mm polystyrene plates. Liquid cultures were incubated at 30 °C on a rotary shaker and solid 
cultures were maintained at 30 °C in an incubator.  
 
Potassium Efflux from S. cerevisiae. 
 The protocol to determine potassium efflux from S. cerevisiae was adapted from a similar 
experiment utilizing C. albicans.46 An overnight culture of S. cerevisiae in YPD was centrifuged 
at 300 g for 5 minutes at 23 C. The supernatant was decanted and the cells were washed twice 
with sterile water. After the second wash step, the cells were suspended in 150 mM NaCl, 5 mM 
HEPES pH 7.4 (Na buffer) to an OD600 of 1.5 (~1x109 CFU/mL) as measured by a Shimadzu 
(Kyoto, Japan) PharmaSpec UV-1700 UV/Vis spectrophotometer. A 3 mL sample of the cell 
suspension was then incubated in a 30 °C aluminum block with stirring for approximately 10 
minutes before data collection. The probe was then inserted and data was collected for 5 minutes 
before adding 30 μL of the compound in question as a 0.3 mM or 3.0 mM solution in DMSO. The 
cell suspension was stirred and data were collected for 30 minutes and then 30 μL of a 1% aqueous 
solution of digitonin was added to effect complete potassium release and data were collected for 
an additional 15 minutes. The experiment was performed independently three times for each small 
molecule.  
 
Data Analysis. 
 The data from each run was normalized to the percent of total potassium release, from 0 to 
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100%. Thus for each experiment a scaling factor S was calculated using the following relationship: 

K  
final
K  
initial
1








 S 100 
Each concentration data point was then multiplied by S before plotting as a function of time. 
 
LUV Preparation.  
 Palmitoyl oleoyl phosphatidylcholine (POPC) was obtained as a 25 mg/mL solution in 
CHCl3 from Avanti Polar Lipids (Alabaster, AL) and was stored at -20 C under an atmosphere of 
dry argon and used within 3 months. A 4 mg/mL solution of ergosterol in CHCl3 was prepared 
monthly and stored at 4 C under an atmosphere of dry argon. Prior to preparing a lipid film, the 
solutions were warmed to ambient temperature to prevent condensation from contaminating the 
solutions. A 13 x 100 mm test tube was charged with 640 L POPC and 230 L of the ergosterol 
solution. The solvent was removed with a gentle stream of nitrogen and the resulting lipid film 
was stored under high vacuum for a minimum of eight hours prior to use. The film was then 
hydrated with 1 mL of 150 mM KCl, 5 mM HEPES pH 7.4 (K buffer) and vortexed vigorously 
for approximately 3 minutes to form a suspension of multilamellar vesicles (MLVs). The resulting 
lipid suspension was pulled into a Hamilton (Reno, NV) 1 mL gastight syringe and the syringe 
was placed in an Avanti Polar Lipids Mini-Extruder. The lipid solution was then passed through a 
0.20 μm Millipore (Billerica, MA) polycarbonate filter 21 times, the newly formed large 
unilamellar vesicle (LUV) suspension being collected in the syringe that did not contain the 
original suspension of MLVs to prevent the carryover of MLVs into the LUV solution. To obtain 
a sufficient quantity of LUVs, three independent 1 mL preparations were pooled together for the 
dialysis and subsequent potassium efflux experiments. The newly formed LUVs were dialyzed 
using Pierce (Rockford, IL) Slide-A-Lyzer MWCO 3,500 dialysis cassettes. The samples were 
dialyzed three times against 600 mL of Na buffer. The first two dialyses were two hours long, 
while the final dialysis was performed overnight.  
 
Determination of Phosphorus Content.  
 Determination of total phosphorus was adapted from the report of Chen and coworkers.9 
The LUV solution was diluted tenfold with Na buffer and three 10 μL samples of the diluted LUV 
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suspension were added to three separate 7 mL vials. Subsequently, the solvent was removed with 
a stream of N2. To each dried LUV film, and a fourth vial containing no lipids that was used as a 
blank, was added 450 μL of 8.9 M H2SO4. The four samples were incubated open to ambient 
atmosphere in a 225 °C aluminum heating block for 25 min and then removed to 23 °C and cooled 
for 5 minutes. After cooling, 150 μL of 30% w/v aqueous hydrogen peroxide was added to each 
sample, and the vials were returned to the 225 °C heating block for 30 minutes. The samples were 
then removed to 23 °C and cooled for 5 minutes before the addition of 3.9 mL water. Then 500 μL 
of 2.5% w/v ammonium molybdate was added to each vial and the resulting mixtures were then 
vortexed briefly and vigorously five times. Subsequently, 500 μL of 10% w/v ascorbic acid was 
added to each vial and the resulting mixtures were then vortexed briefly and vigorously five times. 
The vials were enclosed with a PTFE lined cap and then placed in a 100 °C aluminum heating 
block for 7 minutes. The samples were removed to 23 °C and cooled for approximately 15 minutes 
prior to analysis by UV/Vis spectroscopy. Total phosphorus was determined by observing the 
absorbance at 820 nm and comparing this value to a standard curve obtained through this method 
and a standard phosphorus solution of known concentration. 
 
Determination of Ergosterol Content.  
 Ergosterol content was determined spectrophotometrically. The LUV solution was diluted 
tenfold with Na buffer, and 50 μL of the dilute LUV suspension was added to 450 μL 2:18:9 
hexane:isopropanol:water (v/v/v). Three independent samples were prepared and then vortexed 
vigorously for approximately one minute. The solutions were then analyzed by UV/Vis 
spectroscopy and the concentration of ergosterol in solution was determined by the extinction 
coefficient of 10400 L mol-1 cm-1 at the UVmax of 282 nm and was compared to the concentration 
of phosphorus to determine the percent sterol content. The extinction coefficient was determined 
independently in the above ternary solvent system. LUVs prepared by this method contained 
between 7 and 14% ergosterol.  
 
Efflux from LUVs.  
 The LUV solutions were adjusted to 1 mM in phosphorus using Na buffer. 3 mL of the 1 
mM LUV suspension was added to a 7 mL vial and the solution was gently stirred. The potassium 
ISE probe was inserted and data were collected for one minute prior to the addition of the 
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compound. Then, 30 μL of a 0.1 mM, 1.0 mM, or 3.0 mM DMSO solution of the compound in 
question was added and data were collected for five minutes. Then to effect complete potassium 
release, 30 μL of a 10% v/v solution of triton X-100 was added and data were collected for an 
additional five minutes. The experiment was duplicated with similar results. 
 
Data Analysis. 
 The data from each run were analyzed in the same manner as the efflux data from S. 
cerevisiae. 
 
Antifungal Assays 
Growth Conditions for S. cerevisiae.  
 S. cerevisiae was maintained with yeast peptone dextrose (YPD) growth media consisting 
of 10 g/L yeast extract, 20 g/L peptone, 20 g/L dextrose, and 20 g/L agar for solid media. The 
media was sterilized by autoclaving at 250 °F for 30 min.  Dextrose was subsequently added as a 
sterile 40% w/v solution in water (dextrose solutions were filter sterilized). Solid media was 
prepared by pouring sterile media containing agar (20 g/L) onto Corning (Corning, NY) 100 x 20 
mm polystyrene plates. Liquid cultures were incubated at 30 °C on a rotary shaker and solid 
cultures were maintained at 30 °C in an incubator.  
 
Growth Conditions for C. albicans. 
 C. albicans was cultured in a similar manner to S. cerevisiae except both liquid and solid 
cultures were incubated at 37 °C. 
 
Broth Microdilution Minimum Inhibitory Concentration (MIC) Assay.  
 The protocol for the broth microdilution assay was adapted from the Clinical and 
Laboratory Standards Institute document M27-A2.47 50 mL of YPD media was inoculated and 
incubated overnight at either 30 °C (S. cerevisiae) or 37 °C (C. albicans) in a shaker incubator. 
The cell suspension was then diluted with YPD to an OD600 of 0.10 (~5 x 105 cfu/mL) as measured 
by a Shimadzu (Kyoto, Japan) PharmaSpec UV-1700 UV/Vis spectrophotometer. The solution 
was diluted 10-fold with YPD, and 195 μL aliquots of the dilute cell suspension were added to 
sterile Falcon (Franklin Lakes, NJ) Microtest 96 well plates in triplicate. Compounds were 
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prepared either as 400 μM (AmB, MeAmB) or 2 mM (AmdeB, MeAmdeB) stock solutions in 
DMSO and serially diluted to the following concentrations with DMSO: 1600, 1200, 800, 400, 
320, 240, 200, 160, 120, 80, 40, 20, 10 and 5 μM. 5 μL aliquots of each solution were added to the 
96 well plate in triplicate, with each column representing a different concentration of the test 
compound. The concentration of DMSO in each well was 2.5% and a control well to confirm 
viability using only 2.5% DMSO was also performed in triplicate. This 40-fold dilution gave the 
following final concentrations: 50, 40, 30, 20, 10, 8, 6, 4, 1, 0.5, 0.25 and 0.125 μM. The plates 
were covered and incubated at 30 °C (S. cerevisiae) or 37 °C (C. albicans) for 24 hours prior to 
analysis. The MIC was determined to be the concentration of compound that resulted in no visible 
growth of the yeast. The experiments were performed in duplicate and the reported MIC represents 
an average of two experiments.   
 
Ergosterol Content Determination 
Determination of Ergosterol Standard Curve 
 Ergosterol was prepared as a 0.1 mg/mL stock solution in CHCl3 and serially diluted to the 
following concentrations with CHCl3: 0.1, 0.08, 0.06, 0.03, 0.01 and 0.005 mg/mL. 10 μL aliquots 
of each solution were analyzed by analytical RP-HPLC (Waters Sunfire C18, ODB 5 micron, 4.6 x 
150 mm, 2 mL/min flow rate, MeCN:ethanol (200 proof) 80:20 isocratic over 10 minutes) in 
triplicate. Ergosterol was detected at 280 nm. Ergosterol concentration was plotted against the 
integration of the ergosterol peak (tr = 5.1 min) the data was fitted with a linear least squares fit 
using Excel giving a standard curve. 
 
Determination of Stigmasterol Standard Curve 
 Stigmasterol was prepared as a 4 mg/mL stock solution in toluene and serially diluted to 
the following concentrations with CHCl3: 4, 2, 1, 0.5, 0.25 and 0.125 mg/mL. 10 μL aliquots of 
each solution were analyzed by analytical RP-HPLC (Waters Sunfire C18, ODB 5 micron, 4.6 x 
150 mm, 2 mL/min flow rate, MeCN:ethanol (200 proof) 80:20 isocratic over 10 minutes) in 
triplicate. Stigmasterol was detected at 210 nm. Stigmasterol concentration was plotted against the 
integration of the ergosterol peak (tr = 7.8 min) the data was fitted with a linear least squares fit 
using Excel giving a standard curve. 
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Ergosterol Determination  
 Determination of total ergosterol was adapted from the report of Arnezeder and 
coworkers.33 The starting yeast cultures were prepared identical to the yeast used in the MIC assays. 
50 mL of YPD media was inoculated and incubated overnight at either 30 °C (S. cerevisiae) or 
37 °C (C. albicans) in a shaker incubator. 15 mL of the overnight culture was centrifuged (300 g, 
23 oC) for 5 minutes. The supernatant was decanted and the cells were resuspended in 15 mL of 
Na buffer (150 mM NaCl, 5 mM HEPES, pH 7.4) and centrifuged (300 g, 23 oC) for 5 minutes. 
This process was repeated two additional times and after the third wash, the cells were suspended 
in Na buffer to an OD600 of 1.3 as measured by a Shimadzu (Kyoto, Japan) PharmaSpec UV-1700 
UV/Vis spectrophotometer. 40 mL of the OD600 = 1.3 yeast suspension were centrifuged (600 g, 
23 oC) for 10 minutes. The supernatant was decanted and the cells were resuspended in 50 mL 
sterile water and centrifuged (300 g, 23 oC) for 5 minutes. The supernatant was decanted and the 
resulting yeast pellet was suspended in 10 mL of 0.1 M aqueous HCl and transferred to 40 mL I-
Chem vial. 0.9 mL of a 4 mg/mL standard solution of stigmasterol in toluene was added to the 
sample as an internal standard. The sample was incubated at 90 C for 20 minutes and transferred 
to a 300 mL round bottom flask equipped with a stir bar. The I-Chem vial was washed with 50 mL 
of ethanol and 50 mL of 50% aqueous KOH and the washings were added to the 300 mL round 
bottom flask. The 300 mL round bottom flask was stirred at reflux for 30 minutes and then allowed 
to cool to room temperature. The solution was extracted three times with 30 mL of petroleum ether.  
The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The resulting 
solid was dissolved in 3 mL of 3:1 isopropanol:acetone and filtered through a 0.22 μm low protein 
binding Durapore (PVDF) membrane. 10 µL aliquots of the filtered solution were analyzed by 
analytical RP-HPLC (Waters Sunfire C18, ODB 5 micron, 4.6 x 150 mm, 2 mL/min flow rate, 
MeCN:ethanol (200 proof) 80:20 isocratic over 10 minutes) in triplicate. Ergosterol was detected 
at 280 nm and stigmasterol was detected at 210 nm. Ergosterol and stigmasterol concentrations 
were determined by comparing the integration of the ergosterol peak to the standard curves 
described above. The stigmasterol internal standard was used to adjust the ergosterol concentration 
for any loss of material during the extraction process. The experiment described above was 
repeated in triplicate for both S. cerevisiae and C. albicans. 
 
Determination of Cell Concentration at OD600 = 1.3 
49 
 
 10 μL of the OD600 = 1.3 yeast suspension described above was diluted tenfold with Na 
buffer. 10 μL of the diluted suspension was injected into the INCYTO Neubauer Improved 
Disposable Hemocytometer. Yeast cells were counted with an AMG EVOS fl Microscope. The 
cell concentration determination was repeated in triplicate. 
 
Determination of Cell Concentration in the MIC Assay 
 The overnight cultures S. cerevisiae and C. albicans in YPD that were used in the ergosterol 
determination above were diluted with YPD to an OD600 of 0.10. This was done at the same time 
as the sterol determination experiment above to ensure that the sterol content directly related to the 
cell count. 10 μL of the suspension was injected into the INCYTO Neubauer Improved Disposable 
Hemocytometer. Yeast cells were counted with an AMG EVOS fl Microscope. In the MIC assay, 
an OD600 = 0.10 yeast suspension was diluted 10-fold prior to running the assay so all cell counts 
were divided by 10 to get the cell concentration in the MIC assay. The cell concentration 
determination was repeated in triplicate. 
 
2-9 REFERENCES 
1. Palacios, D. S.; Anderson, T. M.; Burke, M. D. J. Am. Chem. Soc. 2007, 129, 13804-13805. 
2. Palacios, D. S.; Dailey, I.; Siebert, D. M.; Wilcock, B. C.; Burke, M. D. Proc. Natl. Acad. 
Sci. USA 2011, 108, 6733-6738. 
3. Volmer, A. A.; Szpilman, A. M.; Carreira, E. M. Nat. Prod. Rep. 2010, 27, 1329-1349. 
4. Murata, M.; et al. Pure Appl. Chem. 2009, 81, 1123-1129. 
5. Bolard, J. Biochim. Biophys. Acta 1986, 864, 257-304. 
6. Baginski, M.; Resat, H.; Borowski, E. Biochim. Biophys. Acta 2002, 1567, 63-78. 
7. de Kruijff, B.; Demel, R.A. Biochim Biophys Acta 1974, 339, 57-70. 
8. Andreoli, T.E. Ann. NY. Acad. Sci. 1974, 235, 448-468. 
9. Heese-Peck, A.; et al. Mol. Biol. Cell 2002, 13, 2664-2680. 
10. Jin, H.; McCaffery, J. M.; Grote, E. J. Cell. Biol. 2008, 180, 813-826. 
11. Klose, C.; et al. J. Biol. Chem. 2010, 285, 30224-30232. 
12. Kato, M.; Wickner, W. EMBO J. 2001, 20, 4035-4040. 
13. te Welscher, Y. M.; et al. Antimicrob. Agents Chemother. 2010, 54, 2618-2625, 
14. te Welscher, Y. M.; et al. J. Biol. Chem. 2008, 283, 6393-6401. 
50 
 
15. te Welscher, Y. M.; van Leeuwen, M. R.; de Kruijff, B.; Dijksterhuis, J.; Breukink, E. Proc. 
Natl. Acad. Sci. USA 2012, 109, 11156-11159. 
16. Zhang, Y. Q. PLoS Pathog. 2010, 6, e1000939. 
17. Sanglard, D.; Odds, F. C. Lancet Infect. Dis. 2002, 2, 73-85. 
18. Hsuchen, C. –C.; Feingold, D. S. Nature 1974, 251, 656-659. 
19. Vincent, B. M.; Lancaster, A. K.; Scherz-Shouval, R.; Whitesell, L.; Lindquist, S. PLoS Biol. 
2013, 11, e1001692. 
20. Gray, K. C.; et al. Proc. Natl. Acad. Sci. USA 2012, 109, 2234-2239. 
21. Hoogevest, P. V.; de Kruijff, B. Biochim Biophys Acta 1978, 511, 397-407. 
22. Szpilman, A. M.; Manthorpe, J. M.; Carreira, E. M. Angew. Chem. Int. Ed. 2008, 47, 4339-
4342. 
23. Szpilman, A. M.; Cereghetti, D. M.; Manthorpe, J. M.; Wurtz, N. R.; Carreira, E. M. Chem. 
Eur. J. 2009, 15, 7117-7128. 
24. Duplantier, A. J.; Masamune, S. J. Am. Chem. Soc. 1990, 112, 7079-7081. 
25. Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2007, 129, 6716-6717. 
26. Nicolaou, K. C.; Chakraborty, T. K.; Daines, R. A.; Simpkins, N. S. J. Chem. Soc., Chem. 
Commun. 1986, 413-416. 
27. Nicolaou, K. C.; Chakraborty, T. K.; Daines, R. A.; Simpkins, N. S. J. Chem. Soc., Chem. 
Commun. 1987, 686-689. 
28. Nicolaou, K. C.; et al.  J. Am. Chem. Soc. 1988, 110, 4660-4672. 
29. Rogers, B. N.; Selsted, M. E.; Rychnovsky, S. D. Bioorg. Med. Chem. Lett. 1997, 7, 3177-
3182. 
30. Tsuchikawa, H.; Matsushita, N.; Matsumori, N.; Murata, M.; Oishi, T. Tetrahedron Lett. 
2006, 47, 6187-6191. 
31. Lee, S. J.; Anderson, T. M.; Burke, M. D. Angew. Chem. Int. Ed. 2010, 49, 8860-8863. 
32. Klepser, M. E.; Ernst, E. J.; Lewis, R. E.; Ernst, M. E.; Pfaller, M. A. Antimicrob. Agents 
Chemother. 1998, 42, 1207-1212. 
33. Arnezeder, C. H.; Koliander, W.; Hampel, W. A. Anal. Chim. Acta 1989, 225, 129-136. 
34. Taubes, G. Science 2008, 321, 356-361. 
35. Monk, B. C.; Goffeau, A. Science 2008, 321, 367-369 
36. Ellis, D. J. Antimicrob. Chemother. 2002, 49, 7-10. 
51 
 
37. Seco, E. M.; Miranzo, D.; Nieto, C.; Malpartida, F. Appl. Microbiol. Biotechnol. 2010, 85, 
1797-1807. 
38. Cannon, R. D.; et al. Microbiol. 2007, 153, 3211-3217. 
39. Hasper, H. E.; et al. Science 2006, 313, 1636-1637. 
40. Cioffi, A. G.; Hou, J.; Grillo, A. S.; Diaz, K. A.; Burke, M. D. J. Am. Chem. Soc. 2015, 137, 
10096-10099. 
41. Pangborn, A. B; Giardello, M. A; Grubbs, R. H.; Rosen, R. K.; Timmers, F.J. 
Organometallics 1996, 15, 1518-1520. 
42. Still, W,C; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923-2925. 
43. Chen, P.S.; Toribara, T.Y.; Warner, H. Anal. Chem. 1956, 28, 1756-1758. 
44. Heerklotz, H.; Seelig, J. Biochim. Biophys. Acta 2000, 1508, 69-85. 
45. This is a standard protocol for ITC experiments, for example see: te Welscher, Y. M.; ten 
Napel, H. H.; Balague, M. M.; Souza, C. M.; Riezman, H.; de Kruijff, B.; Breukink, E. J. 
Biol. Chem. 2008, 283, 6393-6401. 
46. Hammond SM, Lambert PA, Kliger BN (1974) The mode of action of polyene antibiotics; 
induced potassium leakage in Candida albicans. J Gen Microbiol 81:325-330. 
47. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal 
Susceptibility Testing, M27-A2, Approved Standard 2nd Ed. Vol. 22, Number 15, 2002. 
  
52 
 
CHAPTER 3 
 
DISCOVERY OF A LIGAND-SELECTIVE ALLOSTERIC MODEL IN THE 
DEVELOPMENT OF LESS TOXIC AND RESISTANCE-EVASIVE AMPHOTERICIN B 
DERIVATIVES 
 
 The discovery that sterol binding is the primary mechanism by which amphotericin B 
(AmB) kills cells enables the focus on selective binding for ergosterol over cholesterol in the 
pursuit of less toxic AmB derivatives. However, more selective pharmaceutical actions are 
generally more prone to the development of resistance. To understand whether greater sterol 
selectivity leads to diminished capacity to evade resistance required an atomistic understanding of 
the interaction between AmB and both ergosterol and cholesterol. The leading model predicted the 
C2’ hydroxyl forms a key hydrogen bond to the 3β hydroxyl of both sterols. In contrast to this 
model, deletion or epimerization of the C2’ hydroxyl resulted in selective binding for ergosterol 
over cholesterol and thus substantially diminished toxicity to human cells. A possible reason for 
this selectivity is that the alterations of the C2’ hydroxyl are ligand-selective allosteric 
modifications. Guided by this ligand-selective allosteric modification model, a new class of AmB 
urea derivatives that can be efficiently and scalably accessed from the natural product were 
developed. The AmB ureas showed preferential binding to ergosterol over cholesterol and thus 
were significantly less toxic than AmB to human cells and in mice while maintaining potent 
antifungal activity in vitro and in a murine model of systemic candidiasis. The increase in 
ergosterol selectivity did not impact their ability evade resistance in any appreciable way. 
Therefore, these findings revealed that selective antimicrobial action and the capacity to evade 
resistance are not mutually exclusive and that the derivatives disclosed herein are potential 
candidates to be clinically viable substitutes for AmB.  
 C2'deOAmB was prepared by Dr. Brandon Wilcock and Dr. Brice Uno. C2'epiAmB was 
prepared by Dr. Brice Uno. Deoxycholate formulation of AmB and C2’epiAmB was prepared by 
Lingbowei Hu. AmB urea derivatives were prepared by Dr. Stephen Davis. MIC experiment with 
pathogenic fungal strains and in vivo murine efficacy and toxicity studies were performed by Karen 
Marchillo and Dr. David Andes. All resistance and fitness studies were performed by Dr. Benjamin 
Vincent, Dr. Luke Whitesell, and Prof. Susan Lindquist. Portions of this chapter were adapted 
from Wilcock, B. C.; Endo, M. M.; Uno, B. E.; Burke, M. D. J. Am. Chem. Soc. 2013, 135, 8488-
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8491 and Davis S. A.; Vincent B. M.; Endo, M. M.; Whitesell, L.; Marchillo, K.; Andes, D. R.; 
Lindquist, S.; Burke, M. D. Nat. Chem. Biol. 2015, 11, 481-487. 
 
3-1 BACKGROUND 
  As described in Chapter 2, we determined that AmB primarily kills yeast cells via the 
binding1 and extraction2 of ergosterol. This would suggest that the binding of structurally similar 
mammalian sterol cholesterol would likely account for the toxicity to human cells. Like ergosterol 
for yeast, cholesterol plays a number of essential roles in human physiology, especially for the 
proper functioning of the kidneys. Cholesterol is suggested to be the binding partner for over 250 
human proteins,3 including a number channels4,5 and regulators6 that are important for proper renal 
ion homeostasis. Furthermore, it is vital for renal cytoresistance,7,8 protection from oxidative 
damage,9,10 formation of cell-cell junctions11,12 and caveolae,13 and several signaling pathways.14-
16 Furthermore, another cholesterol-binding small molecule, β-methylcyclodextrin, is also known 
to cause kidney damage in animal models.17,18 Collectively, these studies suggest that the binding 
and extraction of cholesterol may be sufficient to kill human cells and cause nephrotoxicity. These 
findings enables the focus toward increased therapeutic derivatives of AmB to be on maximizing 
the selectivity for ergosterol over cholesterol. However, it has remained unclear if decreases in 
toxicity would come at the cost of AmB’s ability to evade resistance for over half a century19-21 as 
less selective pharmaceutical actions are generally associated with decreased vulnerability to 
pathogen resistance.22,23 
 The continuing increase in antimicrobial resistance has become a growing global health 
crisis. One of the major mechanisms by which resistance develops is mutations to the drug binding 
site.24 This mechanism is highly prevalent as most antimicrobials bind a microbe-specific but 
easily mutable protein. This allows for the selective toxicity but gives rise to the evolution of 
resistance due to the easily mutable nature of the target. An example of this phenomenon are the 
azole antifungals that selectively bind the ergosterol biosynthesis protein lanosterol 14α-
demethylase.25 However, mutations to the binding site of this protein yield azole-resistant strains.26 
Conversely, a protein target has never been identified for AmB and instead it binds a multifaceted 
and vital lipid.1,2 Potentially, AmB’s promiscuous sterol binding is what necessitates the 
substantial changes required for the development of resistance to AmB in vitro, which in turn 
dramatically reduces the pathogenicity. Based on this analysis, the increases in ergosterol 
selectivity would result in the loss of in the resistance-evasive capacity of AmB. 
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3-2 DESIGN OF PROBES TO UNDERSTAND THE ATOMISTIC INTERACTIONS IN THE 
BINDING BETWEEN AmB AND STEROLS 
 In order to rationally design less toxic AmB derivatives that still evade resistance, we 
needed greater atomistic details in the binding between AmB and both ergosterol and cholesterol. 
As discussed in Chapter 2, the deletion of the mycosamine sugar from AmB results in the complete 
loss of sterol binding capacity and thus biological activity.27,28 However, it still remained unclear 
what role each of the heteroatoms of the mycosamine appendage have in this binding event. 
Towards the goal of understanding the atomistic interactions involved in binding between AmB 
and sterols, we pursued functional group deletions on the mycosamine sugar. 
 
Figure 3.1: Mechanistic models of the interaction between AmB and both ergosterol and cholesterol. The axial C2’ hydroxyl is 
predicted to form a hydrogen bond with 3β hydroxyl of both sterols. 
 The leading structural models of the AmB-sterol interaction predicted that the conspicuous 
axial C2’ hydroxyl of AmB forms a critical hydrogen bond with the 3β hydroxyl of both ergosterol 
and cholesterol (Figure 3.1).29-32 However, experimental studies to probe this putative interaction 
have yielded conflicting results. Membrane permeabilization studies with conformationally 
constrained AmB derivatives concluded that this hydrogen bond is critical in the binding for both 
sterols.  In contrast, recent computational studies suggested that this putative hydrogen bond is 
only involved in the binding with ergosterol and not cholesterol.33 Furthermore, a derivative of 
AmB where the C2’ hydroxyl is epimerized and the C41 carboxylate was methyl esterified still 
maintained its antifungal and membrane permeabilization activity.34 However, an additional 
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modification where the epimerized C2’ hydroxyl is methyl etherified caused substantial decreases 
in both activities. While significant, these studies had limitations in understanding the role of the 
C2’ hydroxyl in sterol binding due to the complication of additional steric bulk of the methyl ether 
and that sterol binding was not directly examined. To understand this putative interaction, we 
pursued synthesizing a derivative of AmB where the C2’ hydroxyl was deleted and directly 
determine its impact on the binding to ergosterol and cholesterol. Towards this goal, my colleagues 
Dr. Brandon Wilcock and Dr. Brice Uno synthesized the derivative lacking the C2’ hydroxyl, 
C2’deOAmB.35,36 
 
 
Figure 3.2: Chemical structures of the natural products AmB and its derivatives to probe the atomistic interaction between AmB 
and both ergosterol and cholesterol. 
 
3-3 DISCOVERY OF STEROL-SELECTIVE BINDING AND DIMINISHED TOXICITY OF 
C2'deOAmB 
 The leading structural model displaying a critical interaction between the C2’ hydroxyl and 
sterols would predict that C2'deOAmB would no longer be able to bind ergosterol or cholesterol 
similarly to AmdeB. Sensitive detection of cholesterol binding remained via traditional methods, 
so I developed an optimized ITC-based assay. Towards this pursuit, the concentration of the 
analyte (AmB or its derivative) and the titrant (sterol-containing LUVs) would need to be increased.  
However, AmB's minimal solubility in aqueous buffer severely limited further increases in its 
concentration. I removed the 150 mM KCl from the K buffer utilized in the ITC studies in Chapter 
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2, which had a profound effect on AmB's solubility as we could increase its concentration from 
150 μM up to 600 μM.  
 With the increased concentration of AmB, I tested AmB's capacity to bind ergosterol and 
cholesterol with these optimized conditions. AmB demonstrated a small net exotherm when 
titrated with sterol-free POPC LUVs. I repeated this with 10% ergosterol-containing POPC LUVs 
and consistent with previous reports, I observed a statistically significant increase in net exotherm 
indicating the direct interaction of AmB with ergosterol (Figure 3.3).35 This experiment was 
repeated with 10% cholesterol-containing POPC LUVs and similar to the ergosterol-containing 
LUVs, a statistically significant albeit smaller net increase was observed demonstrating that we 
had an assay to detect cholesterol binding with AmB (Figure 3.3).35 I further validated this assay 
by testing AmdeB through the same series of experiments and observed no increase in net 
exotherm for ergosterol and cholesterol determining that AmdeB doesn't bind either sterol (Figure 
3.3).35 
 
Figure 3.3: Isothermal titration calorimetry with C2’deOAmB titrated with 10% ergosterol-containing, 10% cholesterol-
containing, or sterol-free LUVs. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and NS = not significant. 
 Having validated the optimized ITC assay, I was in position to test the hypothesis that the 
C2' hydroxyl was crucial in binding both sterols with the critical probe C2'deOAmB. When 
titrating C2'deOAmB with ergosterol-containing LUVs, we received the surprising result of a 
strong increase in net exotherm compared to that of the sterol-deficient LUVs (Figure 3.3).35 Thus, 
in stark contrast to the leading model, C2' hydroxyl was not required to bind ergosterol. 
Surprisingly, we alternatively were unable to detect cholesterol binding in this experiment with 
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cholesterol-containing LUVs (Figure 3.3).35 Based on this, the C2' hydroxyl plays a major role in 
the binding of cholesterol, but not ergosterol.  
Based on our mechanistic understanding of AmB described in Chapter 2, we predicted that 
C2'deOAmB would still be toxic to yeast cells, but no longer toxic to human cells. I tested 
C2'deOAmB in microbroth dilution assay and determined its MIC to be 1 μM against both S. 
cerevisiae and C. albicans similar to AmB's MIC for both yeast (Figure 3.4).35 After confirming 
its retained antifungal activity, I tested its toxicity against both human red blood cells and primary 
renal proximal tubule epithelial cells (RPTECs). Up to the limits of solubility in both assays, I 
observed no toxicity to either human cell type similarly to AmdeB (Figure 3.4).35 Based on these 
findings, C2'deOAmB could be a candidate for further development as a potential clinical 
replacement for AmB. 
 
Figure 3.4: In vitro toxicity assays with C2’deOAmB showing MICs from microbroth dilution assays, minimum hemolytic 
concentrations (MHCs) where 90% hemolysis against red blood cells, and minimum toxicity concentrations (MTCs) where 90% 
loss of viability in primary renal proximal tubule epithelial cells (RPTECs). Representative images of primary RPTECs 
administered with small molecule at given concentration. 
 
3-4 DEVELOPMENT OF AN ALLOSTERIC MODIFICATION MODEL FOR STEROL-
SELECTIVE BINDING 
 It remained unclear as to why sterol selective binding was observed upon deletion of the 
C2' hydroxyl. One potential reason is that AmB binds ergosterol and cholesterol in two distinct 
modes. While this possibility has not been ruled out, it is highly unlikely as both sterols are 
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structurally very similar. We instead favored a second model based on the phenomenon of ligand-
selective allosteric effects observed in proteins.37-41 In this model, AmB is capable of binding both 
ergosterol and cholesterol. However, deleting the C2' hydroxyl group results in a shift to a (set of) 
conformation that selectively binds ergosterol over cholesterol. Based on this model, we would 
hypothesize that, similarly to its deoxygenation, the epimerization of the C2' hydroxyl group would 
result in a similar selectivity in sterol binding. 
 Towards testing this model, Dr. Brice Uno synthesized C2'epiAmB in which the C2' 
hydroxyl was epimerized from its native axial position to the equatorial position on the 
mycosamine sugar (Figure 3.2).18 With this probe in hand, I tested its capacity to bind membrane-
embedded ergosterol and cholesterol via the optimized ITC assay I had developed. Similar to 
C2'deOAmB, when titrating C2'epiAmB with ergosterol-containing LUVs, I observed a strong 
difference in net exotherm while titration with cholesterol-containing LUVs resulted in no 
difference (Figure 3.5). As we had hypothesized, like C2'deOAmB, C2'epiAmB demonstrated a 
similar differential in binding affinity for ergosterol over cholesterol.  
 
Figure 3.5: Isothermal titration calorimetry with C2’epiAmB titrated with 10% ergosterol-containing, 10% cholesterol-containing, 
or sterol-free LUVs. ** P ≤ 0.01, *** P ≤ 0.001, and NS = not significant. 
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Figure 3.6: In vitro toxicity assays with C2’epiAmB showing MICs from microbroth dilution assays, minimum hemolytic 
concentrations (MHCs) where 90% hemolysis against red blood cells, and minimum toxicity concentrations (MTCs) where 90% 
loss of viability in primary renal proximal tubule epithelial cells (RPTECs). Representative images of primary RPTECs 
administered with small molecule at given concentration. 
 
To test whether C2'epiAmB's selective binding translated to an increase in therapeutic 
index, I tested its toxicity to both fungal and mammalian cells. Against both S. cerevisiae and C. 
albicans, I observed potent antifungal activity with an MIC of 2 μM for both yeast strains (Figure 
3.6). Furthermore, like C2'deOAmB, C2'epiAmB showed no toxicity with both red blood cells 
(>500 µM) and primary RPTECs (>80 µM) (Figure 3.6). From these results, C2’epiAmB 
represents another potential less toxic candidate for the clinical replacement of AmB.  
 Towards this goal, we pursued the evaluation of C2’epiAmB in invasive candidiasis murine 
models. Administration of AmB in vivo is commonly executed as an intraperitoneal (IP) or 
intravenous (IV) injection with deoxycholate due to poor solubility of AmB in aqueous media. 
Based on the deoxycholate formulation of AmB, my colleague Lingbowei Hu developed a similar 
formulation with C2’epiAmB that enabled us to test C2’epiAmB’s in vivo efficacy and toxicity. 
Having developed the deoxycholate formulation, we collaborated with Dr. David Andes at the 
University of Wisconsin in Madison who had developed the most widely employed mouse model 
of invasive candidiasis.42-44 In this model, neutropenic mice were inoculated with C. albicans and 
then treatment was administered via a single IP injection two hours post-infection at four doses (1 
mg of compound per kg body weight (mg/kg), 4 mg/kg, 8 mg/kg, and 16 mg/kg). Efficacy was 
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evaluated by quantification of kidney fungal burden at 6, 12, and 24 hours post-inoculation. 
Treatment with AmB-deoxycholate at 1 mg/kg yielded a substantial reduction in fungal burden 
(Figure 3.7). However, consistent with the in vitro data, we observed a decrease in in vivo 
antifungal activity with C2’epiAmB-deoxycholate requiring higher administration to reduce the 
fungal burden to similar levels as AmB (Figure 3.7).  
 
Figure 3.7: Efficacy of AmB and C2’epiAmB in mice. Quantification of the fungal burden in the kidneys of neutropenic mice 
infected with C. albicans after 6 hours, 12 hours, and 24 hours post-intraperitoneal injection of AmB or C2’epiAmB at dosages of 
(A) 1 mg per kg body weight, (B) 4 mg per kg body weight, and (C) 16 mg per kg body weight. 
 Despite the reduced efficacy compared to AmB, we determined the acute toxicity in mice 
by administering treatment via a single IV injection to healthy, uninfected mice and monitored for 
lethality over 24 hours. Lethality was first observed for the AmB-deoxycholate-treated mice at 4 
mg/kg administration while complete lethality was observed at the 8 mg/kg dose. In stark contrast, 
all mice treated with even 128 mg/kg of C2’epiAmB-deoxycholate survived with no observable 
toxicity (Figure 3.8). This was highly encouraging as C2’epiAmB showed only a slight attenuation 
of efficacy while demonstrating a substantial decrease in toxicity in vivo.  
 
Figure 3.8: Toxicity of AmB and C2’epiAmB in mice. Dose response toxicity determined by lethality after 24 hour post-
intravenous injection of AmB or C2’epiAmB (four mice per dosage). 
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 Collectively, these results provide additional support for the ligand-selective allosteric 
model. With this model in mind, we noted that the crystal structure of N-iodoacetyl AmB shows a 
prominent water-bridged hydrogen bond between the C2’ hydroxyl and C13 hemiketal (Figure 
3.9).45,46  We reasoned that this crystal structure may represent the ground-state conformation of 
AmB and the deletion or epimerization of the C2’ hydroxyl disrupts this critical stabilizing element 
leading to selective binding of ergosterol over cholesterol.  
While we are still excited in pursuing both C2’deOAmB and C2’epiAmB for further 
development, limited synthetic access to both derivatives has hindered further study. Specifically, 
it has remained unclear whether the improved therapeutic index of both derivatives would come 
at the cost of AmB's resistance-evasive capacity. Furthermore, a viable clinical replacement of 
AmB would need to be accessible on the multiple metric tons to supply the annual global demand. 
Without a practical route toward C2'deOAmB or C2'epiAmB, we sought a different derivative that 
could demonstrate a similar improvement in therapeutic index, but could be potentially accessible 
on scale to meet global demand. 
 
Figure 3.9: Crystal structure of N-iodoacetylAmB showing the water-bridged hydrogen bond between the C2’ hydroxyl and C13 
hemiketal. This model suggests a potential intramolecular salt bridge between the C41 carboxylate and C3’ ammonium.  
 
3-5 STEROL-SELECTIVE BINDING AND DIMINISHED TOXICITY OF AmB UREAS 
 Further analysis of the crystal structure of N-iodoacetylAmB would seem to suggest,29,30 
in addition to the water-bridged hydrogen bond between the C2’ hydroxyl and C13 hemiketal, a 
potential intramolecular salt bridge between the C41 carboxylate and C3’ ammonium ions (Figure 
3.9). We postulated that disruption of this polar interaction could result in sterol-selective binding 
similar to that which was observed with C2’deOAmB and C2’epiAmB.19 Due to its unique 
chemical reactivity, the C41 carboxylate has been modified is several different methods including 
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but not limited to esterification,47,48 amidation,49 and reduction,11,12 which has yielded AmB 
derivatives that have produced modest improvements in therapeutic index. However, all of these 
derivatives maintained the C16-C41 carbon-carbon bond. Dr. Stephen Davis serendipitously 
discovered that diphenyl phosphoryl azide (DPPA) promotes the stereospecific Curtius 
rearrangement to cleave the C16-C41 carbon-carbon bond to form a stable oxazolidonone 
intermediate.50 This oxazolidonone can be mildly opened with methyl amine, ethylene diamine, 
and β-alanine allyl ester to produce the AmB methyl urea (AmBMU), AmB amino urea (AmBAU), 
and AmB carboxylatoethyl urea (AmBCU), respectively. 
 
Figure 3.10: Crystal structure of N-iodoacetylAmB showing the water-bridged hydrogen bond between the C2’ hydroxyl and C13 
hemiketal. This model suggests a potential intramolecular salt bridge between the C41 carboxylate and C3’ ammonium.  
 With this new series of AmB derivatives, I tested their capacities to bind sterols via ITC. 
Like C2’deOAmB and C2’epiAmB, all three AmB urea derivatives retained the capacity to bind 
ergosterol, but within the limits of detection of this experiment, showed no binding to cholesterol.34 
As described in Chapter 2, we previously found that the binding1 and extracting2 of sterol is how 
AmB kills yeast cells, so I analyzed the ability of all three derivatives to extract ergosterol from S. 
cerevisiae membranes using an ultracentrifugation-based membrane isolation assay to quantify the 
amount of ergosterol remaining in the membrane.2 Like AmB, the AmB ureas greatly reduced the 
quantity of ergosterol in these yeast cells,34 demonstrating that they retained the capacities to bind 
and extract ergosterol, but could no longer bind cholesterol. 
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Figure 3.11: Isothermal titration calorimetry with AmBAU, AmBMU, and AmBCU titrated with 10% ergosterol-containing, 10% 
cholesterol-containing, or sterol-free LUVs. ** P ≤ 0.01, *** P ≤ 0.001, and NS = not significant. 
 
 
Figure 3.12: Ergosterol extraction from S. cerevisiae membranes after two hours of treatment with AmB, AmBAU, AmBMU, or 
AmBCU. Values normalized to DMSO control. ** P ≤ 0.01, *** P ≤ 0.001, and NS = not significant. 
 The observed selectivity for ergosterol over cholesterol translated into a substantial 
increase in therapeutic index in vitro. The AmB ureas were tested against S. cerevisiae and human 
red blood cells alongside a series of previously reported AmB derivatives that contained 
modifications at the C41 carboxylate and/or C3’ ammonium. These derivatives included reduction 
of the C41 carboxylate (MeAmB),11,12 esterification to a methyl ester (AmBME),31,32 amidation to 
a methyl amide (AmBMA),33 and a double modified derivative that was reported to have the 
greatest increase in therapeutic index (AmBTABA).51 All of the previously reported derivatives 
produced modest improvements in therapeutic index. Conversely, the AmB urea derivatives 
retained potent antifungal activity, but were remarkably less toxic to human red blood cells with 
the toxicities of AmBMU and AmBAU exceeding 500 µM (Figure 3.13).34 
64 
 
 
Figure 3.13: In vitro toxicity to S. cerevisiae and human red blood cells for AmB, the AmB ureas, and other previously reported 
AmB derivatives with modifications to the C41 carboxylate.  
 
 
Figure 3.14: In vitro toxicity to a panel of pathogenic fungal strains and human renal proximal tubule epithelial cells (RPTECs) 
for AmB and the AmB ureas.  
 Intrigued by substantial increase in therapeutic index for the AmB urea derivatives, we 
performed further in vitro studies with these derivatives. Dr. David Andes tested the ureas against 
a panel of pathogenic Candida, Cryptococcus, and Aspergillus strains including Cryptococcus 
neoformans 89-610 and T1 that are fluconazole resistant52 and Aspergillus fumigatus 11628 and 
14532, which are voriconazole resistant.53 AmBCU was generally less potent than AmBMU and 
AmBAU, which retained near equipotent activity as AmB (Figure 3.14).34 I performed further in 
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vitro toxicity studies with the AmB derivatives against primary human RPTECs54 and human 
telomerase reverse transcriptase 1 (hTERT1) RPTECs.55 The AmB ureas were substantially less 
toxic to both renal cells (Figure 3.14).34  
 
Figure 3.15: Efficacy of AmB, AmBAU, and AmBMU. Quantification of the fungal burden in the kidneys of neutropenic mice 
infected with C. albicans after 2 hours, 6 hours, 12 hours, and 24 hours post-intraperitoneal injection of AmB or C2’epiAmB at 
dosages of (A) 1 mg per kg body weight, (B) 4 mg per kg body weight, and (C) 16 mg per kg body weight. 
 Based on their favored in vitro activity, we continued to evaluate AmBMU and AmBAU 
for their efficacy and toxicity in vivo. Dr. David Andes tested both derivatives for their efficacy in 
his mouse model of candidiasis.26-28 Interestingly, both derivatives were substantially more 
effective than AmB at reducing the fungal burden in the kidneys at all three doses. We speculate 
that this unexpected increase in efficacy may be due to the greater than 20 fold increase in water 
solubility compared to AmB.34 Both compounds were then tested for their acute mouse toxicity 
via single intravenous injection. All the mice died from treatment with AmB at a dose of 4 mg/kg 
within seconds of administration. Conversely, AmBAU became greater than 50% lethal at a dose 
of 64 mg/kg.34 Furthermore, AmBMU showed no lethality even up to 64 mg/kg.34 These 
derivatives lend further support for our ligand-selective allosteric model and represent a 
fascinating platform for AmB derivatives that can be easily accessed on large scale and 
demonstrate a substantial increase in therapeutic index.  
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Figure 3.16: Toxicity of AmB, AmBAU, and AmBMU in mice. Dose response toxicity determined by lethality after 24 hour post-
intravenous injection of AmB, AmBAU, and AmBMU (five mice per dosage). 
 
3-6 AmB UREAS MAINTAIN RESISTANCE-EVASIVE ABILITY 
 At this point, the question still remained whether improvement in the therapeutic index 
came at the cost of the ability to evade resistance. Due to its unique mechanism of action,1 AmB 
is not susceptible to the major mechanisms of antimicrobial resistance as its lipid target is not 
easily mutable as protein or RNA targets and it is not a substrate for secretion via efflux pumps or 
drug detoxifying enzymes.56 Furthermore, ergosterol plays a major role in a vast array of processes 
in yeast physiology.57-61 Additionally, mutations to genes involved in ergosterol biosynthesis can 
alter the sterol structure and/or content of the membrane enabling AmB resistance in vitro.62 
However, these mutations have a considerable fitness cost in vivo, which substantially reduces 
fungal virulence63 and would explain why clinically relevant resistance to AmB is incredibly 
rare.64  
 To test whether the improved sterol selectivity of AmBAU and AmBMU had impacted 
their ability to evade resistance, we collaborated with Dr. Benjamin Vincent, Dr. Luke Whitesell, 
and Prof. Susan Lindquist at the Massachusetts Institute of Technology. We compared the MICs 
of AmB, AmBAU, and AmBMU against a panel of lab-generated C. albicans strains that contained 
mutations to seven different nonessential ergosterol biosynthesis genes. Interestingly, AmBAU 
and AmBMU had in vitro profiles very similar to that of AmB where only the erg2, erg6, and 
erg3erg11 mutants had any substantial resistance (Figure 3.17A).34 All three mutations are known 
to result in avirulence in yeast47 likely due to the inability for many ergosterol-dependent proteins 
to utilize this mutated sterol. As a result, all known mutations to nonessential ergosterol 
biosynthesis genes do not seem to a threat to the efficacy of both urea derivatives. 
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Figure 3.17: (A) MICs for AmB, AmBAU, and AmBMU against lab-generated strains with mutations in seven nonessential 
ergosterol biosynthesis genes. MICs for (B) tert-butyl peroxide and (C) geldanamycin for various AmBAU- and AmBMU-resistant 
strains. (D) Representative images of filamentation in response to fetal bovine serum at 37°C, stained with Calcofluor white, scale 
bar 10 µm. (E) In vivo competitive fitness study (F) Overall mice survival following inoculation with AmB-resistant pool, AmBAU-
resistant pool, AmBMU-resistant pool, a pool of parental wild-type, and a pool of five passaged and mutagenized wild-type 
mutants. Figure was adapted from reference 34. 
 To understand if there are additional mutations that could result in resistance to AmB, 
AmBAU, or AmBMU, resistance mutants were generated via gradual resistance-selection in liquid 
culture and five to eight mutants were created for each small molecule. Importantly, all resistant 
mutants were cross-resistant across all three molecules, which would suggest there were no new 
mechanisms of resistance from the two AmB urea derivatives.34 Genome sequencing of the 
mutants revealed that contained mutations in the ERG2 or ERG6 locus and subsequently 
underwent loss of heterozygosity. AmB-resistant mutants had previously been shown to 
substantial defects in fitness and are highly sensitive to oxidative stress that are consistently 
encountered during the infection process.47 Similar to AmB-resistant mutants, all of the mutants 
resistant to AmBAU or AmBMU were found to be extremely sensitive to the oxidative stressors 
tert-butyl hydrogen peroxide (Figure 3.17B) and the Hsp90 inhibitor geldanamycin (Figure 3.17C). 
Moreover, wild-type yeast readily filament in vitro, which is thought to play an important role in 
virulence in Candida (Figure 3.17D).65,66 AmB-resistant mutations result in the crippling of the 
ability to filament and thus lead to avirulence in yeast.47 Similarly, we found that in response to 
stimulation with fetal bovine serum, AmBAU- and AmBMU-resistant mutants were also unable 
to filament (Figure 3.17D).34  
 Encouraged by these in vitro fitness studies, we tested whether resistance to AmBAU or 
AmBMU would likewise reduce fitness in vivo. Mice were infected with a pool of yeast strains 
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comprised of one strain of the wild-type (AmBAU- and AmBMU-sensitive) and 15 strains that 
were AmBAU- or AmBMU-resistant (with each strain comprising of 1/16th of the total population). 
The infection was allowed to progress untreated for four days. Following infection, fungal colonies 
were isolated from the kidneys and tested for their sensitivity to AmBAU and AmBMU. Based on 
those results, the fraction of AmBAU- and AmBMU-resistant were determined from the total 
population isolated from the kidneys. Over the course of just four days, the percentage of AmBAU- 
or AmBMU-resistant strains dropped substantially and were overtaken by the AmBAU- and 
AmBMU-sensitive wild-type strain (Figure 3.17E).34  
 As a final analysis of in vivo fitness, we tested whether AmBAU- or AmBMU-resistant 
mutants had retained the ability to cause lethal infection. Mice were infected with pools of AmB-, 
AmBAU-, or AmBMU-resistant mutants and were compared to the survival of the mice infected 
by wild-type strains. A low inoculum of the wild-type strain resulted in complete lethality for all 
mice over the two week analysis window (Figure 3.17F). Similarly, infection of wild-type strains 
that had undergone random mutagenesis over five in vitro passages like the resistant mutants also 
killed all mice (Figure 3.17F). In stark contrast, all mice inoculated with AmB-, AmBAU-, or 
AmBMU-resistant strains survived the infection over the two week period. (Figure 3.17F).34 
Collectively, these results demonstrate that AmBAU and AmBMU are not any more vulnerable to 
the development of resistance than AmB, which has managed to evade resistance for over half a 
century. Therefore, these findings reveal that selective antimicrobial action and the capacity to 
evade resistance are not mutually exclusive and have the potential to be clinically viable substitutes 
for AmB.  
 
3-7 THESIS SUMMARY 
 This thesis describes the mechanistic understanding of the ion channel-forming, 
antimycotic natural product, AmB. To probe the roles of ergosterol binding and membrane 
permeabilization in the antifungal activity of AmB, a derivative lacking the C35 hydroxyl group, 
C35deOAmB, was synthesized using an iterative cross-coupling (ICC)-based strategy. This 
critical probe retained the capacity to bind ergosterol, could no longer cause membrane 
permeabilization, and was able to maintain potent but slightly reduced antifungal activity. Its 
antifungal activity was comparable to natamycin, another member of the polyene macrolide family 
that similarly binds ergosterol and notably does not form ion channels. Deletion of the mycosamine 
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appendage from AmB and natamycin eliminates the ability to bind ergosterol and thus abrogates 
the antifungal activity of both natural products. Collectively, these results demonstrate that the 
primary mechanism by which AmB and likely all mycosamine-containing polyene macrolides kill 
yeast is via mycosamine-mediated ergosterol binding and that the capacity to permeabilize 
membranes only further increases their potency. 
 This finding has substantial implications in the mechanistic understanding of how AmB 
kills human cells and causes nephrotoxicity. It suggests that the operative mechanism for killing 
human cells is the binding of the major mammalian sterol: cholesterol. To further probe the 
atomistic interactions involved in the binding between AmB and both sterols, a derivative of AmB 
lacking the C2’ hydroxyl was synthesized. This hydroxyl was predicted to be key in the binding 
with both ergosterol and cholesterol. Conversely, C2’deOAmB maintained the capacity to bind 
ergosterol but not cholesterol and thus maintained potent antifungal activity but was substantially 
less toxic to human cells. To explain this sterol selectivity, a ligand-selective allosteric 
modification model was developed. Consistent with this model, epimerization of the C2’ hydroxyl 
resulted in C2’epiAmB which shared a similar activity profile with C2’deOAmB. Guided by this 
model, a new class of AmB derivatives were synthesized: the AmB ureas. Like both C2’-modified 
derivatives, the AmB ureas had increased selectivity for ergosterol over cholesterol and were 
significantly less toxic than AmB. Due to the accessibility of this new class of AmB derivatives, 
they were further evaluated for efficacy and toxicity in a mouse model of disseminated candidiasis 
and found to be more efficacious and less toxic than AmB in vivo. Furthermore, the AmB ureas 
still maintained the ability to evade resistance.   
Collectively, the studies described in this thesis significantly advances the mechanistic 
understanding of this critically important natural product. These findings enable the pursuit of 
increased therapeutic derivatives of AmB to focus on maximizing the binding selectivity for 
ergosterol over cholesterol. Furthermore, these results lay the foundation towards utilizing the ion 
channel forming capacity of AmB as a molecular surrogate for missing protein ion channels that 
underlie a number of human diseases.  
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3-8 EXPERIMENTAL SECTION 
Materials.  
Commercially available materials were purchased from Sigma-Aldrich, AKSci, Alfa Aesar, 
Strem, Avanti Polar Lipids, Lipoid, Silicycle, or Fisher Scientific and were used without further 
purification unless stated otherwise. Amphotericin B was a generous gift from Bristol-Myers 
Squibb Company. All solvents were dispensed from a solvent purification system that passes 
solvents through packed columns according to the method of Pangborn and coworkers67 (THF, 
Et2O, CH2Cl2, toluene, dioxane, hexanes : dry neutral alumina; DMSO, DMF, CH3OH : activated 
molecular sieves). Water was obtained from a Millipore MilliQ water purification system.  
 
Isothermal Titration Calorimetry 
General Information. 
 Experiments were performed using a NanoITC isothermal titration calorimeter (TA 
Instruments, Wilmington, DE).  Solutions of the compounds to be tested were prepared by diluting 
a 60.0 mM stock solution of the compound in DMSO to 600 M with K buffer (5.0 mM 
HEPES/KHEPES, pH = 7.4). The final DMSO concentration in the solution was 1% v/v. POPC 
LUVs were prepared and phosphorus and ergosterol content was quantified as described below. 
The LUV solutions were diluted with buffer and DMSO to give a final phospholipid concentration 
of 12.0 mM in a 1% DMSO/K buffer solution. Immediately prior to use, all solutions were 
incubated at 37°C for 30 minutes and degassed under vacuum at 37°C for 10 minutes. The 
reference cell of the instrument (volume = 0.190 mL) was filled with a solution of 1% v/v DMSO/K 
buffer. 
 
LUV Preparation.  
 Palmitoyl oleoyl phosphatidylcholine (POPC) was obtained as a 20 mg/mL solution in 
CHCl3 from Avanti Polar Lipids (Alabaster, AL) and was stored at -20C under an atmosphere of 
dry argon and used within 1 month. A 4 mg/mL solution of ergosterol in CHCl3 was prepared 
monthly and stored at 4C under an atmosphere of dry argon. A 4 mg/mL solution of cholesterol 
in CHCl3 was prepared monthly and stored at 4C under an atmosphere of dry argon. Prior to 
preparing a lipid film, the solutions were warmed to ambient temperature to prevent condensation 
from contaminating the solutions. A 13 x 100 mm test tube was charged with 800 L POPC and 
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230 L of the ergosterol solution. For cholesterol-containing liposomes, a 13 x 100 mm test tube 
was charged with 800 L POPC and 224 L of the cholesterol solution. For sterol-free liposomes, 
a 13 x 100 mm test tube was charged with 800 L POPC. The solvent was removed with a gentle 
stream of nitrogen and the resulting lipid film was stored under high vacuum for a minimum of 
eight hours prior to use. The film was then hydrated with 1 mL of K buffer and vortexed vigorously 
for approximately 3 minutes to form a suspension of multilamellar vesicles (MLVs). The resulting 
lipid suspension was pulled into a Hamilton (Reno, NV) 1 mL gastight syringe and the syringe 
was placed in an Avanti Polar Lipids Mini-Extruder. The lipid solution was then passed through a 
0.20 μm Millipore (Billerica, MA) polycarbonate filter 21 times, the newly formed large 
unilamellar vesicle (LUV) suspension being collected in the syringe that did not contain the 
original suspension of MLVs to prevent the carryover of MLVs into the LUV solution.  
 
Determination of Phosphorus Content.  
 Determination of total phosphorus was adapted from the report of Chen and coworkers.68 
The LUV solution was diluted tenfold with K buffer and three 10 μL samples of the diluted LUV 
suspension were added to three separate 7 mL vials. Subsequently, the solvent was removed with 
a stream of N2. To each dried LUV film, and a fourth vial containing no lipids that was used as a 
blank, was added 450 μL of 8.9 M H2SO4. The four samples were incubated open to ambient 
atmosphere in a 225°C aluminum heating block for 25 min and then removed to 23°C and cooled 
for 5 minutes. After cooling, 150 μL of 30% w/v aqueous hydrogen peroxide was added to each 
sample, and the vials were returned to the 225°C heating block for 30 minutes. The samples were 
then removed to 23°C and cooled for 5 minutes before the addition of 3.9 mL water. Then 500 μL 
of 2.5% w/v ammonium molybdate was added to each vial and the resulting mixtures were then 
vortexed briefly and vigorously five times. Subsequently, 500 μL of 10% w/v ascorbic acid was 
added to each vial and the resulting mixtures were then vortexed briefly and vigorously five times. 
The vials were enclosed with a PTFE lined cap and then placed in a 100°C aluminum heating 
block for 7 minutes. The samples were removed to 23°C and cooled for approximately 15 minutes 
prior to analysis by UV/Vis spectroscopy. Total phosphorus was determined by observing the 
absorbance at 820 nm and comparing this value to a standard curve obtained through this method 
and a standard phosphorus solution of known concentration. 
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Determination of Ergosterol Content.  
 Ergosterol content was determined spectrophotometrically. A 50 μL portion of the LUV 
suspension was added to 450 μL 2:18:9 hexane:isopropanol:water (v/v/v). Three independent 
samples were prepared and then vortexed vigorously for approximately one minute. The solutions 
were then analyzed by UV/Vis spectroscopy and the concentration of ergosterol in solution was 
determined by the extinction coefficient of 10400 L mol-1 cm-1 at the UVmax of 282 nm and was 
compared to the concentration of phosphorus to determine the percent sterol content. The 
extinction coefficient was determined independently in the above ternary solvent system. LUVs 
prepared by this method contained between 7 and 14% ergosterol.  
 
Titration Experiment. 
 Titrations were performed by injecting the LUV suspension at ambient temperature into 
the sample cell (volume = 0.191 mL) which contained the 600 M solution of the compound in 
question at 25°C. The volume of the first injection was 0.23 μL. Consistent with standard 
procedure,69 due to the large error commonly associated with the first injection of ITC 
experiments, the heat of this injection was not included in the analysis of the data. Next, six 7.49 
L injections of the LUV suspension were performed. The spacing between each injection was 
720 seconds to ensure that the instrument would return to a stable baseline before the next injection 
was made. The rate of stirring for each experiment was 300 rpm.  
 
Data Analysis. 
 NanoAnalyze software (TA Instruments) was used for baseline determination and 
integration of the injection heats, and Microsoft Excel was used for subtraction of dilution heats 
and the calculation of overall heat evolved. To correct for dilution and mixing heats, the heat of 
the final injection from each run was subtracted from all the injection heats for that particular 
experiment.70 By this method, the overall heat evolved during the experiment was calculated using 
the following formula: 
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Where i = injection number, n = total number of injections, 
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= heat of the ith injection, 
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= the heat of the final injection of the experiment.  
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Antifungal Assays 
Growth Conditions for S. cerevisiae.  
 S. cerevisiae was maintained with yeast peptone dextrose (YPD) growth media consisting 
of 10 g/L yeast extract, 20 g/L peptone, 20 g/L dextrose, and 20 g/L agar for solid media. The 
media was sterilized by autoclaving at 250°F for 30 min.  Dextrose was subsequently added as a 
sterile 40% w/v solution in water (dextrose solutions were filter sterilized). Solid media was 
prepared by pouring sterile media containing agar (20 g/L) onto Corning (Corning, NY) 100 x 20 
mm polystyrene plates. Liquid cultures were incubated at 30°C on a rotary shaker and solid 
cultures were maintained at 30°C in an incubator.  
 
Growth Conditions for C. albicans. 
 C. albicans was cultured in a similar manner to S. cerevisiae except both liquid and solid 
cultures were incubated at 37°C. 
 
Growth Conditions and MIC Assay for C. albicans, C. tropicalis, C. parapsilosis, and C. 
glabarata. 
The organisms were maintained, grown, subcultured, and quantified on Sabouraud 
dextrose agar (SDA; Difco Laboratories, Detroit, MI). 24 hours prior to the study, the organisms 
were subcultured at 35°C.  MIC determinations were performed in duplicate on at least two 
occasions using the Clinical and Laboratory Standards Institute M27-A3 microbroth 
methodology.71 
 
Growth Conditions and MIC Assay for C. neoformans. 
C. neoformans MIC was determined as previously reported after 48 hours.36   
 
Growth Conditions and MIC Assay for C. fumigatus. 
The organisms were maintained, grown, subcultured, and quantified on potato dextrose 
agar (PDA; Difco Laboratories, Detroit, MI). MIC determinations were performed in duplicate on 
at least two occasions using the Clinical and Laboratory Standards Institute M28-A2 microbroth 
methodology72 at 48 hours. 
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Broth Microdilution Minimum Inhibitory Concentration (MIC) Assay.  
 The protocol for the broth microdilution assay was adapted from the Clinical and 
Laboratory Standards Institute document M27-A2.73 50 mL of YPD media was inoculated and 
incubated overnight at either 30°C (S. cerevisiae) or 37°C (C. albicans) in a shaker incubator. The 
cell suspension was then diluted with YPD to an OD600 of 0.10 (~5 x 105 cfu/mL) as measured by 
a Shimadzu (Kyoto, Japan) PharmaSpec UV-1700 UV/Vis spectrophotometer. The solution was 
diluted 10-fold with YPD, and 195 μL aliquots of the dilute cell suspension were added to sterile 
Falcon (Franklin Lakes, NJ) Microtest 96 well plates in triplicate. Compounds were prepared either 
as 400 μM (AmB, MeAmB) or 2 mM (AmdeB, MeAmdeB) stock solutions in DMSO and serially 
diluted to the following concentrations with DMSO: 1600, 1200, 800, 400, 320, 240, 200, 160, 
120, 80, 40, 20, 10 and 5 μM. 5 μL aliquots of each solution were added to the 96 well plate in 
triplicate, with each column representing a different concentration of the test compound. The 
concentration of DMSO in each well was 2.5% and a control well to confirm viability using only 
2.5% DMSO was also performed in triplicate. This 40-fold dilution gave the following final 
concentrations: 50, 40, 30, 20, 10, 8, 6, 4, 1, 0.5, 0.25 and 0.125 μM. The plates were covered and 
incubated at 30°C (S. cerevisiae) or 37°C (C. albicans) for 24 hours prior to analysis. The MIC 
was determined to be the concentration of compound that resulted in no visible growth of the yeast. 
The experiments were performed in duplicate and the reported MIC represents an average of two 
experiments.   
 
Hemolysis Assays 
Erythrocyte Preparation.  
 The protocol for the hemolysis assay was adapted from the report of Paquet and 
coworkers.35 Whole human blood (sodium heparin) was purchased from Bioreclamation LLC 
(Westbury, NY) and stored at 4°C and used within two days of receipt.  To a 2.0 mL eppendorf 
tube, 1 mL of whole human blood was added and centrifuged at 10,000 g for 2 minutes.  The 
supernatant was removed and the erythrocyte pellet was washed with 1 mL of sterile saline and 
centrifuged at 10,000 g for 2 minutes.  The saline wash was repeated for a total of three washes.  
The erythrocyte pellet was suspended in 1 mL of RBC buffer (10 mM NaH2PO4, 150 mM NaCl, 
1 mM MgCl2, pH 7.4) to form the erythrocyte stock suspension.   
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Minimum Hemolysis Concentration (MHC) Assay. 
 Compounds were prepared as 1.03 mM (AmB) or 12.8 mM (C2'deOAmB and AmdeB) 
stock solutions in DMSO and serially diluted to the following concentrations with DMSO: 7689, 
5126, 2563, 2050, 1538, 1025, 769, 513, 384, 256, 205, 154, 103, 77, 51, 26 μM.  To a 0.2 mL 
PCR tube, 24 μL of RBC buffer and 1 μL of compound stock solution were added, which gave 
final concentrations of 500, 300, 200, 100, 80, 60, 40, 30, 20, 15, 10, 8, 6, 4, 3, 2, 1 μM.  Positive 
and negative controls were prepared by adding 1 μL of DMSO to MilliQ water or RBC buffer, 
respectively to 0.2 mL PCR tube.  To each PCR tube, 0.63 μL of the erythrocyte stock suspension 
was added and mixed by inversion.  The samples were incubated at 37°C for 2 hours.  The samples 
were mixed by inversion and centrifuged at 10,000 g for 2 minutes.  15 μL of the supernatant from 
each sample was added to a 384-well place.  Absorbances were read at 540 nm using a Biotek H1 
Synergy Hybrid Reader (Wanooski, VT).  Experiments were performed in triplicate and the 
reported MHC represents an average of three experiments. 
 
Data Analysis. 
 Percent hemolysis was determined according to the following equation: 
 
% ℎ𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 =  
𝐴𝑏𝑠.𝑠𝑎𝑚𝑝𝑙𝑒− 𝐴𝑏𝑠.𝑛𝑒𝑔.
𝐴𝑏𝑠.𝑝𝑜𝑠.− 𝐴𝑏𝑠.𝑛𝑒𝑔.
 × 100% 
 
Concentration vs. percent hemolysis was plotted and fitted to 4-parameter logistic (4PL)74 dose 
response fit using OriginPro 8.6. The MHC was defined as the concentration to cause 90% 
hemolysis.   
 
WST-8 Cell Proliferation Assays 
Primary Renal Proximal Tubule Epithelial Cells Preparation.  
 Primary human renal proximal tubule epithelial cells (RPTECs) were purchased from 
ATCC (Manassas, VA) and immediately cultured upon receipt.  Complete growth media was 
prepared using renal epithelial cell basal medium (ATCC, PCS-400-030), renal epithelial cell 
growth kit (ATCC, PCS-400-040), and penicillin-streptomycin (10 units/mL and 10 µg/mL).  
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Complete media was stored at 4°C in the dark and used within 28 days.  Primary RPTECs were 
grown in CO2 incubator at 37°C with an atmosphere of 95% air/5% CO2.   
 
WST-8 Reagent Preparation. 
 WST-8 cell proliferation assay kit (10010199) was purchased from Cayman Chemical 
Company (Ann Arbor, MI) and stored at -20 °C and used within 6 months of receipt. WST-8 
reagent and electron mediator solution were thawed and mixed to prepare the WST-8 reagent 
solution. The solution was stored at -20 °C and used within one week.   
 
WST-8 Assay. 
 A suspension of primary or TERT1 RPTECs in complete growth media was brought to a 
concentration of 1 x 105 cells/mL. A 96-well plate was seeded with 99 μL of the cell suspension 
and incubated at 37°C with an atmosphere of 95% air/5% CO2 for 3 hours. Positive and negative 
controls were prepared by seeding with 100 μL of the cell suspension or 100 μL of the complete 
media. Compounds were prepared as 5 mM (AmB) and 8 mM (AmdeB, C2'deOAmB, C2'epiAmB, 
AmBAU, AmBMU, and AmBCU) stock solutions in DMSO and serially diluted to the following 
concentrations with DMSO: 8000, 6000, 4000, 3000, 2000, 1500, 1000, 800, 600, 400, 300, 200, 
100, 50, 25, 10, 5, 2.5, 1, 0.5, 0.25, and 0.1 μM. 1 μL aliquots of each solution were added to the 
96-well plate in triplicate, with each column representing a different concentration of the test 
compound. The 96-well plate was incubated at 37°C with an atmosphere of 95% air/5% CO2 for 
24 hours. After incubation, the media was aspirated and 100 μL of serum-free media was added 
and 10 μL of the WST-8 reagent solution was added to each well. The 96-well plate was mixed in 
a shaking incubator at 200 rpm for 1 minute and incubated at 37°C with an atmosphere of 95% 
air/5% CO2 for 2 hours.  Following incubation, the 96-well plate was mixed in a shaking incubator 
at 200 rpm for 1 minute and absorbances were read at 450 nm using a Biotek H1 Synergy Hybrid 
Reader (Wanooski, VT).  Experiments were performed in triplicate and the reported cytotoxicity 
represents an average of three experiments.   
 
Data Analysis. 
 Percent hemolysis was determined according to the following equation: 
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% 𝑐𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
𝐴𝑏𝑠.𝑠𝑎𝑚𝑝𝑙𝑒− 𝐴𝑏𝑠.𝑛𝑒𝑔.
𝐴𝑏𝑠.𝑝𝑜𝑠.− 𝐴𝑏𝑠.𝑛𝑒𝑔.
 × 100% 
Concentration vs. percent hemolysis was plotted and fitted to 4-parameter logistic (4PL)56 
dose response fit using OriginPro 8.6.  The MTC was defined as the concentration to cause 90% 
loss of cell viability.   
 
Microscopy. 
Cells were imaged using an AMG (Bothell, WA) EVOS fl Microscope after treatment with 
DMSO (vehicle) or the compounds at the indicated concentrations for 24 hours. Images were taken 
using transmitted light at 10x objective. 
 
In Vivo Sterol Extraction Studies and Membrane Isolation. 
This assay was performed similar to that previously described.2 Specifically, 75 mL 
overnight cultures of Saccharomyces cerevisiae were grown to stationary phase (OD ~1.7) in YPD 
media at 30°C, shaking. 49.5 mL of this culture was transferred to a 50 mL Falcon centrifuge tubes.  
Cells were treated with 500 μL of DMSO, 500 μM AmB, 500 μM AmBAU, 500 μM 
AmBMU, or 500 μM AmBCU (final compound concentration of 5 μM). Falcon tubes were 
incubated in the shaking incubator at 30°C for 2 hours. Tubes were inverted at the 1 hour timepoint 
to resuspend. 
Yeast membranes were isolated using a modified version of Haas’ spheroplasting and 
isosmotic cell lysis protocol and differential ultracentrifugation. After treatment time, tubes were 
centrifuged for 5 minutes at 3000 g at 23°C. The supernatant was decanted and 5 mL of wash 
buffer (milliQ H2O (89%), 1M aq. DTT (1%), and 1M aq. Tris buffer pH 9.4 (10%)) was added. 
Tubes were vortexed to resuspend and incubated in a 30°C water bath for 10 minutes. Tubes were 
then centrifuged for 5 minutes at 3000 g at 23°C and the supernatant decanted. 
1 mL of spheroplasting buffer (1M aq. potassium phosphate buffer pH 7.5 (5%), 4M aq. 
sorbitol (15%), and YPD media (80%)) and 100 μL of a 5 mg/mL aq. solution of lyticase from 
Arthrobacter luteus (L2524 Sigma-Aldrich) was added to each tube, vortexed to resuspend. Tubes 
were incubated in a 30°C shaking incubator for 30 minutes. After incubation, tubes were 
centrifuged for 10 minutes at 1080 g at 4°C and the supernatant decanted. 
78 
 
1 mL of PBS buffer and 20 μL of a 0.4 mg/ml dextran in 8% Ficoll solution was added to 
each tube, mixed very gently to resuspend. This suspension was placed in an ice bath for 4 minutes 
and then transferred to a 30°C water bath for 3 minutes.  
The suspensions were transferred to 2 mL Eppendorf tubes, vortexed to ensure complete 
lysis, and centrifuged at 15,000 g at 4°C to remove un-lysed cells and cell debris. The resulting 
supernatants were transferred to thick-wall polycarbonate ultracentrifuge tubes (3.5 mL, 13 x 51 
mm, 349622 Beckman Coulter). PBS buffer was added to the tubes to bring the volume up to ~3 
mL. The tubes were centrifuged for 1 hour at 100,000 g at 4°C in a Beckman Coulter TLA-100.3 
fixed-angle rotor in a tabletop ultracentrifuge. The supernatant was poured off. The remaining 
membrane pellet was resuspended in 1 mL PBS buffer. 750 μL of the suspension was transferred 
to a 7 mL vial and stored at -80°C until further analysis. 
 
Gas chromatography quantification of sterols. 
The suspension was allowed to warm to room temperature and 20 μL of internal standard 
(4 mg/mL cholesterol in chloroform) was added. They were dissolved in 3 mL 2.5% ethanolic 
KOH, which was vortexed gently, capped, and heated in a heat block on a hot plate at 90°C for 1 
hour. The vials were allowed to cool to room temperature. 1 mL of brine was added to the contents 
of each vial. Extraction was performed three times, each with 2 mL of hexane. Organic layers were 
combined, dried over MgSO4, filtered through Celite® 545, and transferred to another 7 mL vial. 
The contents of the vial were concentrated in vacuo. The lipid films were dried on high vac with 
P2O5 for 30 minutes to remove residual water. 
To the resulting lipid films, 100 μL pyridine and 100 μL N,O-
Bis(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane (T6381-10AMP Sigma-
Aldrich) was added and vortexed gently. This solution was heated at 60°C for 1 hour to produce 
TMS ethers. The vials were placed in an ice bath and the solvent was evaporated off by nitrogen 
stream. Vials were kept at low temperature to prevent evaporation of the sterol ethers along with 
the solvent. The resulting films were resuspended in 100 μL of decane, filtered using a Supelco 
ISO-Disc PTFE Filter (4 mm x 0.2 µm) and transferred to a GC vial insert for analysis.  
Gas chromatography analysis was carried out on an Agilent 7890A gas chromatograph 
equipped with FID and Agilent GC 7693 Autosampler. Samples were separated on a 30 m, 0.320 
mm ID, 0.25 um film HP-5 capillary column (19091J-413 Agilent). Hydrogen was employed as a 
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carrier gas with a flow rate of 4 mL/min. Nitrogen make-up gas, hydrogen gas, and compressed 
air were used for the FID. A split/splitless injector was used in a 20:1 split. The injector volume 
was 2 μL. The column temperature was initially held at 250°C for 0.5 min, then ramped to 265°C 
at a rate of 10oC /min with a final hold time of 12.5 min. The injector and detector temperature 
were maintained at 270°C and 290°C, respectively. 
 
Ethics Statement 
All animal procedures were approved by the Institutional Animal Care and Use Committee 
at the University of Wisconsin according to the guidelines of the Animal Welfare Act, The Institute 
of Laboratory Animal Resources Guide for the Care and Use of Laboratory Animals, and Public 
Health Service Policy. 
 
In Vivo Murine Efficacy Study 
All studies were approved by the Animal Research Committee of the William S. Middleton 
Memorial VA Hospital (Madison, WI). Efficacy was assessed by CFU count in the kidneys of 
neutropenic mice with a disseminated fungal infection as described previously by Andes et al.26-
28 A clinical isolate of Candida albicans (K-1) was grown and quantified on SDA. For 24 hours 
prior to infection, the organism was subcultured at 35°C on SDA slants. A 106 CFU/mL inoculum 
(CFU, colony forming units) was prepared by placing six fungal colonies into 5 mL of sterile, 
depyrogenated normal (0.9%) saline warmed to 35°C. Six-week-old ICR/Swiss specific-pathogen-
free female mice were obtained from Harlan Sprague Dawley (Madison, WI). The mice were 
weighed (23−27 g) and given intraperitoneal injections of cyclophosphamide to render neutropenia 
(defined as <100 polymorphonuclear leukocytes/mm3). Each mouse was dosed with 150 mg/kg of 
cyclophosphamide 4 days prior to infection and 100 mg/kg 1 day before infection. Disseminated 
candidiasis was induced via tail vein injection of 100 μL of inoculum. AmB, AmBAU, or AmBMU 
were reconstituted with 1.0 mL of 5% dextrose. Each animal in the treatment group was given a 
single 200 μL intraperitoneal (ip) injection of reconstituted AmB, AmBAU, or AmBMU 2 hours 
post-infection. Doses were calculated in terms of mg of compound/kg of body weight. At each 
time point (6, 12, and 24 hours post-infection), three animals per experimental condition were 
sacrificed by CO2 asphyxiation. The kidneys from each animal were removed and homogenized. 
The homogenate was diluted serially 10-fold with 9% saline and plated on SDA. The plates were 
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incubated for 24 hours at 35°C and inspected for CFU viable counts. The lower limit of detection 
for this technique is 100 CFU/mL. All results are expressed as the mean log10 CFU per kidney for 
three animals.  
  
In Vivo Murine Toxicity Study 
All studies were approved by the Animal Research Committee of the William S. Middleton 
Memorial VA Hospital (Madison, WI). Uninfected Swiss ICR mice were used for assessment of 
infusion toxicity. Groups of five mice were treated with single intravenous doses of AmB, 
AmBAU, AmBMU (reconstituted with 1.0 mL of 5% dextrose), or sterile pyrogen-free 0.85% 
NaCl administered via the lateral tail vein over 30 seconds. Dose levels studies included 0.5, 1, 2, 
4, 8, 16, 32, and 64 mg/kg. Following administration mice were observed continuously for one 
hour and then every 6 hours up to 24 hours for signs of distress or death.  
 
Resistance Studies 
Minimum Inhibitory Concentration and Growth Assays 
Susceptibility of wild-type and resistant strains to AmB, AmBAU, AmBMU, tert-butyl 
peroxide (Sigma-Aldrich), geldanamycin and radicicol (A.G. Scientific) was determined in flat 
bottom, 96-well microtiter plates (Costar) using a broth microdilution protocol adapted from CLSI 
M27-A3. Overnight cultures (14-20 hr) were grown at 30°C in YPD, and approximately 5x103 
cells were seeded per well. For AmB, AmBAU, and AmBMU, MIC assays were performed at 
37°C in RPMI buffered with MOPS (0.165M) with 10% fetal bovine serum (Sigma-Aldrich) 
added; for tert-butyl peroxide, geldanamycin, and radicicol, MIC’s were determined in YPD at 
30°C. MIC’s were determined after 24 h incubation as the concentration of compound resulting in 
no visible growth in wells.  For quantitative display of growth at drug dilutions, OD600 was 
measured in a spectrophotometer (Tecan) and displayed as heat maps using Java TreeView 1.1.3 
(http://jtreeview.sourceforge.net).  
 
Media and Growth Conditions 
C. albicans was generally grown and maintained as described previously15. Stocks were 
stored in 15% glycerol at -80°C; strains were generally grown in YPD media at 30°C. Drugs were 
added directly to media from DMSO stocks. 
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In Vitro Gradual Selection of AmB, AmBAU, or AmBMU Resistance 
 Selection of resistance to AmB, AmBAU, and AmBMU was performed as follows. 1 mL 
overnight (14-20 hr) cultures of SC5314 (WT) were washed in PBS, then treated with 3% ethyl 
methanesulfonate (EMS) for 45 min. Cells were then washed 4x in YPD and resuspended in YPD 
and allowed to recover for 3 h.  Cells were then inoculated to an OD600 of approximately 0.025-
0.05 in 100 mL YPD containing 0.25 μM AmB or AmB-AU, or 0.375 μM AmB-MU. After 24-72 
hours, a 1 mL aliquot was removed from any culture that had grown to saturation and subjected to 
another round of mutagenesis in the same manner as described above. After recovery, cells were 
then inoculated into a new YPD flask containing 2x higher concentration of the same drug. 
Cultures that grew were subjected to one more round of EMS mutagenesis before inoculating into 
a 2-fold higher drug concentration (total of 3 rounds of EMS mutagenesis) and then passaged at 
2-fold higher increments of drug concentration until reaching 2 μM AmB or AmB-AU, or 3 μM 
AmB-MU. Cultures were passaged once more at 2 μM AmB or AmBAU or 3 μM AmBMU, then 
plated onto YPD media and frozen in glycerol stocks before further evaluation.   
 
Filamentation Assay 
Hyphal induction was performed by growing C. albicans overnight at 30°C in YPD, 
washing in PBS, and diluting 1:100 into RPMI+10% fetal bovine serum (Sigma-Aldrich) at 37°C 
in a culture tube on a rotating wheel. After 3 h, cultures were washed in PBS and resuspended in 
250 µg/mL Calcofluor white in a microcentrifuge tube, and shaken at 30°C for 10 min.  Cells were 
then washed twice in PBS, concentrated 10-fold, briefly sonicated in a water bath, and mounted 
on slides for visualization under a DAPI filter set at 60X magnification. 
 
Murine Model of Systemic Infection 
All animal protocols were performed in accordance with the Guide for the Care and Use 
of Laboratory Animals of the National Institutes of Health. Animals were maintained according to 
the guidelines of the MIT Committee on Animal Care (CAC). These studies were approved by the 
MIT CAC (protocol #0312-024-15). We used 7-12-week-old female Balb/c mice ordered from 
Taconic farms for all mouse virulence studies.  All strains were prepared for inoculation by diluting 
overnight cultures (14-20 h) 1:100 into YPD and growing into log phase for 4-5 hours, then 
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washing 3x in PBS before. Strains were injected into the lateral tail vein in a volume of 100 μl.  
For mouse survival experiments, strains were grouped as follows: The wild-type Mutagenized pool 
consisted of 5 SC5314 colonies subjected in parallel to mutagenesis and passaging (as described 
above) without drug exposure, injected as of 1.6x105 cfu per strain (8x105 cfu total inoculum per 
mouse); the Wild-type low inoculum was the SC5314 parental strain injected at 1.6x105 cfu.  
AmB-Resistant, AmBAU-Resistant, and AmBMU-resistant pools were comprised of strains 
isolated from each selection in the presence of the indicated drug, using strains that exhibited >4-
fold MIC increase for the drug used.  Individual resistant strains were present in the pools at 
1.6x105 cfu per mouse (8x105 total inoculum per mouse when pooled). Each strain or pool of 
strains was tested in at least two independent experiments, and data were pooled. Mice were 
weighed daily and monitored for signs of morbidity and sacrificed when body weight decreased 
by 20%, or when signs of extreme distress were apparent.  For the competitive infection with 
quantification of kidney burden, a pool comprised of 16 strains at equal fraction of the population, 
one SC5314 wild-type and 5 strains each from selections for resistance to AmB, AmBAU, and 
AmBMU was used, with 3x104 cells of each strain inoculated per mouse (4.8x105 total inoculum).  
Three mice were used per experiment, in a total of two experiments. 4 days after infection, mice 
were sacrificed and kidneys were removed aseptically, homogenized, and plated onto YPD plates.  
Pools of the inoculum immediately before injection were also plated. 184 colonies were randomly 
selected from the pre-infection and 184 from the post-infection plates and tested for growth in 96-
well plates in the presence of 1 μM AmBAU or 1.5 μM AmBMU, and the fraction of wells from 
the pre and post-infection pools exhibiting growth in either drug was determined.  
 
Whole Genome Sequencing, Alignment, Mapping, and Variant Calling 
Whole genome sequencing and analysis was performed as previously described47. 
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